<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0106210758
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Evenity
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ROMOSOZUMAB
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        105
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Subcutaneous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection in pre-filled syringe
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Pre-filled syringe
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        Store in a refrigerator (2°C – 8°C), do not freeze
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        1809
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="AMGEN MANUFACTURING LIMITED" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            AMGEN MANUFACTURING LIMITED
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 530]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Salehiya Trading Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Amgen Inc.
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        M05BX06
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>EVENITY is a prescription medicine used to:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; treat osteoporosis (thinning and weakening of bone) in women after menopause (&ldquo;change of life&rdquo;) who:</p><p>o&nbsp;&nbsp; are at high risk of fracture (broken bone), or</p><p>o&nbsp;&nbsp; cannot use another osteoporosis medicine or other osteoporosis medicines did not work well.</p><p>It is not known if EVENITY is safe and effective in children.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>EVENITY can cause serious side effects, including:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased risk of having a heart attack, stroke, or death from a cardiovascular (heart or blood vessel) problem.</p><p>Call your healthcare provider or get emergency help right away if you have any of the symptoms listed below.</p><p>o&nbsp;&nbsp;&nbsp; Symptoms of <strong>heart attack</strong> may include:</p><p>o&nbsp;&nbsp; chest pain or pressure</p><p>o&nbsp;&nbsp; shortness of breath</p><p>o&nbsp;&nbsp; feeling light-headed or dizzy</p><p>o&nbsp;&nbsp;&nbsp; Symptoms of <strong>stroke</strong> may include:</p><p>o&nbsp;&nbsp; headache</p><p>o&nbsp;&nbsp; numbness or weakness in face, arm, or legs</p><p>o&nbsp;&nbsp; difficulty talking</p><p>o&nbsp;&nbsp; changes in vision or loss of balance</p><p>&nbsp;</p><p>Before you receive EVENITY, tell your healthcare provider if you have had a heart attack or stroke, especially if it has happened in the past year.</p><p>See section <strong>&ldquo;Possible side effects&rdquo;</strong> below for other side effects of EVENITY.</p><p><strong>&nbsp;</strong></p><p><strong>Do not use EVENITY if you:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have been told by your healthcare provider that your blood calcium level is too low.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are allergic to romosozumab or any of the ingredients in EVENITY. See the end of this package leaflet for a complete list of ingredients in EVENITY.</p><p>&nbsp;</p><p><strong>Before receiving EVENITY, tell your healthcare provider about all your medical conditions, including if you:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have a history of other heart or blood vessel problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have low blood calcium</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cannot take daily calcium and vitamin&nbsp;D</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have kidney problems or are on kidney dialysis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; plan to have dental surgery or teeth removed</p><p>&nbsp;</p><p><strong>Tell your healthcare provider about all the medicines you take,</strong> including prescription and over-the-counter medicines, vitamins, and herbal supplements.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding </strong></p><p>EVENITY is only intended to treat women after menopause.</p><p>EVENITY should not be used by women of child-bearing potential, or when pregnant or breast-feeding. It is not known whether EVENITY may harm an unborn or breast-fed child.</p><p>Contact your doctor if you have any questions.</p><p>&nbsp;</p><p><strong>Driving and using machines </strong></p><p>EVENITY is expected to have no effect or very little effect on the ability to drive and use machines.</p><p>&nbsp;</p><p><strong>EVENITY contains sodium </strong></p><p>This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say, essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EVENITY is an injection that will be given to you by your healthcare provider. EVENITY is injected under your skin (subcutaneous).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You will receive an EVENITY dose (2&nbsp;injections) 1 time every month for 12&nbsp;doses.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You should take calcium and vitamin D while you receive EVENITY.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you miss a dose of EVENITY, contact your healthcare provider as soon as possible to schedule your next dose. Your next dose of EVENITY should then be scheduled every month from the date of the last injection.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You should take good care of your teeth and gums while you receive EVENITY. You should tell your dentist that you are receiving EVENITY before you have dental work.</p><p>&nbsp;</p><p><strong>If you use more EVENITY than you should </strong></p><p>If, by mistake, you have used more EVENITY than you should, contact your doctor or pharmacist.</p><p>&nbsp;</p><p><strong>If you forget to use or cannot take EVENITY at your usual time </strong></p><p>If you miss a dose of EVENITY, contact your doctor as soon as possible to schedule another dose. Thereafter, the next dose should be given not earlier than one month after the date of the last dose.</p><p>&nbsp;</p><p><strong>If you stop taking EVENITY </strong></p><p>If you are considering stopping EVENITY treatment, please discuss this with your doctor. Your doctor will advise you on how long you should be treated with EVENITY.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>EVENITY may cause serious side effects, including:</strong></p><p>See section <strong>&ldquo;What you need to know before you use EVENITY&rdquo;</strong></p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Serious allergic reactions.</strong> Serious allergic reactions have happened in people who receive EVENITY. Call your healthcare provider or go to the nearest emergency room right away if you have any symptoms of a serious allergic reaction. Symptoms of a serious allergic reaction may include:</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>o&nbsp;&nbsp; rash</p><p>o&nbsp;&nbsp; hives</p><p>o&nbsp;&nbsp; swelling of the face, lips, mouth, tongue, or throat which may cause difficulty in swallowing or breathing</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Low calcium levels in your blood (hypocalcemia). </strong>EVENITY may lower the calcium levels in your blood. Your low blood calcium should be treated before you receive EVENITY. Call your healthcare provider if you have symptoms of low blood calcium such as:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>o&nbsp;&nbsp; spasms, twitches, or cramps in your muscles</p><p>o&nbsp;&nbsp; numbness or tingling in your fingers, toes or around your mouth</p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Severe jaw bone problems (osteonecrosis). </strong>Severe jaw bone problems may happen when you take EVENITY. Your healthcare provider should examine your mouth before you start EVENITY.</p><p>o&nbsp; Your healthcare provider may tell you to see your dentist before you start EVENITY. Ask your healthcare provider or dentist about good mouth care.</p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Unusual thigh bone fractures. </strong>Symptoms of this type of fracture include:</p><p>o&nbsp; new or unusual pain in your hip, groin, or thigh.</p><p><strong>&nbsp;</strong></p><p><strong>The most common side effects of EVENITY include:</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; joint pain</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>These are not all the possible side effects of EVENITY.</p><p>&nbsp;</p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>How to store EVENITY</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep EVENITY in a refrigerator at 2&deg;C to 8&deg;C in the original carton to protect it from light.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not freeze EVENITY.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not shake EVENITY.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; When you remove EVENITY from the refrigerator, EVENITY must be kept at room temperature up to 25&deg;C in the original carton and must be used within 30&nbsp;days. EVENITY should be thrown away if taken out of the refrigerator and not used within 30&nbsp;days.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not keep EVENITY at temperatures above 25&deg;C. Warm temperatures will affect how EVENITY works.</p><p><strong>&nbsp;</strong></p><p><strong>Keep EVENITY and all medicines out of the reach of children.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What EVENITY contains</strong></p><p>Each single use prefilled syringe (90&nbsp;mg/mL) delivers 1.17&nbsp;mL of solution containing 105&nbsp;mg of romosozumab, acetate (3.8&nbsp;mg), calcium (0.61&nbsp;mg), polysorbate 20&nbsp;(0.07&nbsp;mg) and sucrose (70&nbsp;mg) in Water for Injection and sodium hydroxide to a pH of&nbsp;5.2.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What EVENITY looks like and contents of the pack

EVENITY is a clear to opalescent, colourless to light yellow solution for injection provided in a single use disposable pre-filled pen. The syringe inside the pen is made of plastic with a stainless steel needle.

Pack size of 2 pre-filled pens.

Not all pack sizes may be marketed..
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder:</strong></p><p>Amgen Inc.</p><p>One Amgen Center Drive</p><p>Thousand Oaks, CA 91320-1799, USA</p><p><strong>&nbsp;</strong></p><p><strong>Site of Manufacture of the Drug Product:</strong></p><p>Patheon Italia S.p.A.</p><p>Viale Gian Battista Stucchi 110,</p><p>Monza, - 20900 Italy</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in April 2019.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">إیڤینیتي هو دواء يعطى بموجب وصفة طبية ويستخدم لـ:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; علاج هشاشة العظام (ترقق العظم وضعفه) لدى النساء بعد انقطاع الطمث (&quot;تغير الحياة&quot;) اللواتي:</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يكن معرضات بشدة لخطر الإصابة بكسور (تكسر العظام)، أو</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا يمكنهن تناول دواء آخر لعلاج هشاشة العظام أو لم تكن أدوية هشاشة العظام الأخرى فعالة.</p><p dir="RTL">لم يتبين بعد ما إذا كان إیڤینیتي آمنا وفعالا لدى الأطفال.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>قد يسبب إیڤینیتي آثارا جانبية خطيرة، تشمل:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة خطر الإصابة بنوبة قلبية أو سكتة دماغية أو الوفاة نتيجة مشكلة قلبية وعائية (مرتبطة بالقلب أو الأوعية الدموية).</p><p dir="RTL">اتصل بمقدم الرعاية الصحية أو التمس المساعدة الطارئة فور ظهور أي من الأعراض المدرجة أدناه.</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تشمل أعراض <strong>النوبة القلبية</strong>:</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم أو ضغط في الصدر</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق التنفس</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالدوار أو الدوخة</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تشمل أعراض <strong>السكتة الدماغية</strong>:</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تنميل أو ضعف في الوجه أو الذراع أو الساقين</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في التحدث</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في الرؤية أو فقدان التوازن</p><p dir="RTL">قبل أن تتناول إیڤینیتي، أخبر مقدم الرعاية الصحية إذا كنت قد أصبت مسبقا بنوبة قلبية أو سكتة دماغية، خاصة إذا كان قد حدث ذلك في السنة الأخيرة.</p><p dir="RTL">راجع القسم <strong>&quot;ماهي الآثار الجانبية المحتملة لإیڤینیتي؟&quot;</strong> أدناه للاطلاع على الآثار الجانبية الأخرى لإیڤینیتي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لا تتناول إیڤینیتي إذا:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أخبرك مقدم الرعاية الصحية أن مستوى الكالسيوم في دمك منخفض جدا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني من حساسية تجاه روموسوزوماب أو أي من مكونات إیڤینیتي. راجع القسم الأخير من هذه النشرة الطبيــــة &nbsp;للحصول على قائمة كاملة بالمكونات الموجودة في إیڤینیتي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قبل أن تتناول إیڤینیتي، أخبر مقدم الرعاية الصحية عن كل ظروفك الصحية، بما في ذلك:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كان لديك تاريخ مرضي لوجود مشاكل أخرى في القلب أو الأوعية الدموية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كان مستوى الكالسيوم في دمك منخفضا</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كان يتعذر عليك تناول الكالسيوم وفيتامين&nbsp;د يوميا</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كان لديك مشاكل كلوية أو كنت تخضع لغسيل كلى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت تخطط لإجراء جراحة أسنان أو قلع بعض الأسنان</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>أخبر مقدم الرعاية الصحية عن كل الأدوية التي تتناولها،</strong> بما في ذلك الأدوية التي تعطى بموجب وصفة طبية وتلك التي لا تحتاج وصفة طبية والفيتامينات والمكملات العشبية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL">الغرض من إیڤینیتي<strong> </strong>هو علاج النساء بعد انقطاع الطمث فقط.</p><p dir="RTL">يجب عدم استخدام إیڤینیتي<strong> </strong>من قبل النساء في سن الإنجاب أو أثناء الحمل أو الرضاعة. من غير المعروف ما إذا كان إیڤینیتي<strong> </strong>قد يؤذي الجنين أو الطفل أثناء الرضاعة الطبيعية.</p><p dir="RTL">اتصل بطبيبك إذا كان لديك أي أسئلة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">من المتوقع ألا يكون لـ إیڤینیتي<strong> </strong>أي تأثير أو أن يكون له تأثير ضئيل للغاية على القدرة على القيادة واستخدام الآلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي إیڤینیتي </strong><strong>على الصوديوم</strong></p><p dir="RTL">يحتوي هذا الدواء على أقل من 1 مليمول صوديوم (23 ملغ) لكل جرعة، وهذا يعني أنه أساسا &quot;خالٍ من الصوديوم&quot;.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إیڤینیتي هو عبارة عن حقنة تعطى إليك من طرف مقدم الرعاية الصحية الخاص بك. يتم حقن إیڤینیتي تحت الجلد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ستحصل على جرعة إیڤینیتي (حقنتان) مرة كل شهر وبمعدل ١٢&nbsp;جرعة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب أن تتناول الكالسيوم وفيتامين د أثناء تلقيك إیڤینیتي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا فوّت جرعة من إیڤینیتي، فاتصل بمقدم الرعاية الصحية الخاص بك في أسرع وقت ممكن لتحديد موعد لجرعتك التالية. بعد ذلك، يجب وضع جدول لتلقي جرعات إیڤینیتي التالية كل شهر اعتبارا من موعد آخر حقنة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب أن تعتني جيدا بأسنانك ولثتك أثناء تلقيك إیڤینیتي. وعليك إخبار طبيب أسنانك بأنك تتلقى إیڤینیتي قبل أن يقوم بأي عمل في أسنانك.</p><p dir="RTL"><strong><u>&nbsp;</u></strong></p><p dir="RTL"><strong>إذا كنت تستخدم</strong><strong> إیڤینیتي</strong><strong> أكثر مما ينبغي</strong></p><p dir="RTL">إذا استخدمت عن طريق الخطأ إیڤینیتي أكثر مما ينبغي ، فاتصل بطبيبك أو الصيدلي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا نسيت استخدام أو لم تستطع تناول</strong><strong> إیڤینیتي في وقتك المعتاد</strong></p><p dir="RTL">إذا فاتتك جرعة من إیڤینیتي ، فاتصل بطبيبك في أقرب وقت ممكن لتحديد جرعة أخرى. بعد ذلك ، يجب إعطاء الجرعة التالية في موعد لا يتجاوز شهر واحد بعد تاريخ آخر جرعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا توقفت عن تناول</strong><strong> إیڤینیتي</strong></p><p dir="RTL">إذا كنت تفكر في إيقاف العلاج بإیڤینیتي ، يرجى مناقشة هذا الأمر مع طبيبك. سينصحك طبيبك بالمدة التي يجب أن تعالج فيها&nbsp; بإیڤینیتي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>قد يسبب إیڤینیتي آثارا جانبية خطيرة، تشمل:</strong></p><p dir="RTL">راجع قسم <strong>&quot; ماهي المعلومات المطلوب الإلمام بها قبل استخدام إیڤینیتي&quot;</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>تفاعلات تحسسية خطيرة.</strong> حدثت ردود فعل تحسسية خطيرة لدى أشخاص يتلقون إیڤینیتي. اتصل بمقدم الرعاية الصحية أو توجه إلى أقرب غرفة طوارئ على الفور في حالة إصابتك بأي أعراض تفاعل تحسسي خطر. قد تشمل أعراض التفاعل التحسسي الخطر ما يلي:</p><table dir="rtl" border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><ul><li dir="RTL">طفح جلدي</li><li dir="RTL">شرى</li><li dir="RTL">حالات تورم في الوجه أو الشفاه أو الفم أو اللسان أو الحلق، ما قد يؤدي إلى صعوبة في البلع أو التنفس</li></ul></td></tr></tbody></table><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>انخفاض مستويات الكالسيوم في دمك (نقص كالسيوم الدم).</strong> قد يؤدي إیڤینیتي إلى انخفاض مستويات الكالسيوم في دمك. يجب معالجة انخفاض مستوى الكالسيوم في الدم قبل تلقي إیڤینیتي. اتصل بمقدم الرعاية الصحية إذا ظهر لديك أي من أعراض انخفاض مستوى الكالسيوم في الدم، ومنها:</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><ul><li dir="RTL">تشنجات أو ارتجافات أو تقلصات في العضلات</li><li dir="RTL">شعور بالتنميل أو النخز في أصابع يديك أو قدميك أو حول فمك</li></ul></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>مشاكل حادة في عظمة الفك (النخر العظمي).</strong> قد تحدث مشاكل حادة في عظمة الفك عندما تتناول إیڤینیتي. يجب أن يفحص مقدم الرعاية الصحية فمك قبل أن تبدأ في تناول إیڤینیتي.</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يطلب منك مقدم الرعاية الصحية زيارة طبيب الأسنان قبل البدء في تناول إیڤینیتي. اسأل مقدم الرعاية الصحية أو طبيب الأسنان عن كيفية العناية بالفم بشكل جيد.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>كسور غير مألوفة في عظم الفخذ.</strong> تشمل أعراض هذا النوع من الكسور:</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالة جديدة أو غير معتادة من الألم في منطقة الورك أو الأربية أو الفخذ.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>تشمل الآثار الجانبية الأكثر شيوعا لإیڤینیتي:</strong></p><table dir="rtl" border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><ul><li dir="RTL">ألم المفاصل</li></ul></td><td style="vertical-align:top"><ul><li dir="RTL">الصداع</li></ul></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL">هذه ليست كل الآثار الجانبية المحتملة لإیڤینیتي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا تعرضت لأي آثار جانبية، يرجى إبلاغ طبيبك أو الصيدلي أو الممرضة. ويشمل ذلك أي آثار جانبية محتملة غير مدرجة في هذه النشرة. من خلال الإبلاغ عن الآثار الجانبية، يمكنك أن تساعد في توفير مزيد من المعلومات حول سلامة هذا الدواء.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>٥.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كيفية حفظ إیڤینیتي</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احتفظ بدواء إیڤینیتي في الثلاجة عند درجة حرارة تتراوح ما بين ٢&deg;م و٨&deg;م في علبته الأصلية لحمايته من الضوء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تجمد إیڤینیتي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا ترج إیڤینیتي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عندما تخرج إیڤینیتي من الثلاجة، يجب إبقاؤه في درجة حرارة الغرفة حتى ٢٥&deg;م في علبته الأصلية واستخدامه في غضون ٣٠&nbsp;يوما. يجب التخلص من إیڤینیتي في حالة إخراجه من الثلاجة وعدم استخدامه في غضون ٣٠&nbsp;يوما.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تحتفظ بدواء إیڤینیتي في درجات حرارة تتجاوز ٢٥&deg;م، إذ أن درجات الحرارة العالية تؤثر على كيفية عمل إیڤینیتي.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>احتفظ بـإیڤینیتي وكل الأدوية بعیدا عن متناول الأطفال.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>كل حقنة مملوءة مسبقا للاستخدام مرة واحدة (٩٠&nbsp;مجم/مل) توفر ١٫١٧&nbsp;مل من المحلول الذي يحتوي على ١٠٥&nbsp;مجم من الروموسوزوماب والأسيتات (٣٫٨&nbsp;مجم) والكالسيوم (٠٫٦١&nbsp;مجم) والبوليسوربات&nbsp;٢٠&nbsp;(٠٫٠٧&nbsp;مجم) والسكروز (٧٠&nbsp;مجم) في ماء للحقن وهيدروكسيد الصوديوم إلى حدود حمضية قدرها&nbsp;٥٫۲.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>شكل إیڤینیتي ومحتويات العبوة</strong></p><p dir="RTL">إیڤینیتي<strong> </strong>هو محلول للحقن صاف إلى لامع، عديم اللون إلى أصفر فاتح، في شكل قلم جاهز للاستخدام مرة واحدة. إن الحقنة داخل القلم مصنوعة من البلاستيك مع إبرة من الفولاذ المقاوم للصدأ.</p><p dir="RTL">&nbsp;</p><p dir="RTL">حجم العلبة 2 أقلام مملوءة مسبقا.</p><p dir="RTL">قد لا يتم تسويق جميع أحجام العبوات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>حامل تفويض التسويق:</strong></p><p dir="RTL">Amgen Inc.</p><p dir="RTL">One Amgen Center Drive</p><p dir="RTL">‫,Thousand Oaks, CA 91320-1799</p><p dir="RTL">الولایات المتحدة الأمریكیة</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>موقع التصنیع الأولي:</strong></p><p dir="RTL">‪Patheon Italia S.p.A.</p><p dir="RTL">‪Viale Gian Battista Stucchi 110,</p><p dir="RTL">Monza, - 20900‫</p><p dir="RTL">إيطاليا</p><p dir="RTL">‫</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            	تم آخر اعتماد لهذه النشرة في أبريل ٢٠١٩.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                EVENITY 105 mg solution for injection in pre-filled syringe for subcutaneous use
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Romosozumab is a humanized monoclonal antibody (IgG2) produced in a mammalian cell line (Chinese Hamster Ovary) by recombinant DNA technology that binds to and inhibits sclerostin. 
Romosozumab has an approximate molecular weight of 149 kDa.
Injection: 105 mg/1.17 mL (90 mg/mL) clear to opalescent, colorless to light yellow solution in a single use prefilled syringe. 
A full dose of EVENITY requires two single use prefilled syringes.
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
EVENITY (romosozumab) injection is supplied as a sterile, preservative free, clear to opalescent, colorless to light yellow solution for subcutaneous injection in a single use prefilled syringe.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>4.1.1&nbsp;&nbsp;&nbsp; Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture</p><p>EVENITY is indicated for the treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy.</p><p>4.1.2&nbsp;&nbsp;&nbsp; Limitations of Use</p><p>The anabolic effect of EVENITY wanes after 12 monthly doses of therapy. Therefore, the duration of EVENITY use should be limited to 12 monthly doses. If osteoporosis therapy remains warranted, continued therapy with an anti-resorptive agent should be considered <em>[see Posology and method of administration<strong> </strong>(4.2) and Clinical Studies (5.5)]</em>.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Important Dosage and Administration Instructions</p><ul><li>Two separate syringes (and two separate subcutaneous injections) are needed to administer the total dose of 210&nbsp;mg of EVENITY. Inject two 105&nbsp;mg/1.17&nbsp;mL prefilled syringes, one after the other.</li></ul><ul><li>EVENITY should be administered by a healthcare provider.</li></ul><p>&nbsp;</p><p>4.2.2&nbsp;&nbsp;&nbsp; Recommended Dosage</p><ul><li>The recommended dose of EVENITY is 210&nbsp;mg administered subcutaneously in the abdomen, thigh or upper arm. Administer EVENITY once every month.</li><li>The treatment duration for EVENITY is 12 monthly doses.</li><li>Patients should be adequately supplemented with calcium and vitamin D during treatment with EVENITY <em>[see Special Warnings and Precautions for use (4.4) and Clinical Studies (5.5)]</em>.</li><li>If the EVENITY dose is missed, administer as soon as it can be rescheduled. Thereafter, EVENITY can be scheduled every month from the date of the last dose.</li></ul><p>&nbsp;</p><p>4.2.3&nbsp;&nbsp;&nbsp; Preparation and Administration Instructions</p><p><strong>&nbsp;</strong></p><p><strong>Step 1: Prior to Administration:</strong></p><ul><li>Remove two syringes from the carton.</li><li>Visually inspect EVENITY for particles and discoloration prior to administration. EVENITY is a clear to opalescent, colorless to light yellow solution. Do not use if the solution is cloudy or discolored or contains particles.</li><li>Do not use the syringe if<ul><li>any part appears cracked or broken</li><li>the gray needle cap is missing or not securely attached</li><li>the expiration date printed on the label has passed</li></ul></li><li>Always hold the prefilled syringe by the syringe barrel to remove the syringe from the tray. See Figure A.</li></ul><p>o&nbsp;&nbsp; Do not grasp the plunger rod.</p><ul><li><ul><li>Do not grasp the gray needle cap.</li><li>Do not remove the gray needle cap until you are ready to inject.</li></ul></li><li>Allow EVENITY to sit at room temperature for at least 30&nbsp;minutes before injecting. Do not warm in any other way <em>[see Special precautions for storage (6.4)]</em>.</li></ul><p>&nbsp;</p><p><!--[if gte vml 1]><v:shapetype id="_x0000_t202"
 coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="Text_x0020_Box_x0020_23" o:spid="_x0000_s1031"
 type="#_x0000_t202" style='position:absolute;margin-left:212.35pt;
 margin-top:1.25pt;width:81.45pt;height:43.6pt;z-index:251660288;visibility:visible;
 mso-wrap-style:square;mso-width-percent:0;mso-height-percent:200;
 mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:text;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:200;
 mso-width-relative:margin;mso-height-relative:margin;v-text-anchor:top'
 o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF
dyTewfKKEqcMCKEmHfgZgaE8wMW+SSwc27JvS/v23KTJgkoXFsu+P+c7Ol5vDoMTe0zZBl/LVVlJ
gV4HY31Xy4/tS3EvRSbwBlzwWMsjZrlprq/W22PELHjb51r2RPFBqax7HCCXIaLnThvSAMTP1KkI
+gs6VLdVdad08ISeCho1ZLN+whZ2jsTzgcsnJwldluLxNDiyagkxOquB2Knae/OLUsyEkjenmdzb
mG/YhlRnCWPnb8C898bRJGtQvEOiVxjYhtLOxs8AySiT4JuDystlVV4WPeM6tK3VaILeDZxIOSsu
ti/jidNGNZ3/J08yC1dNv9v8AAAA//8DAFBLAwQUAAYACAAAACEArTA/8cEAAAAyAQAACwAAAF9y
ZWxzLy5yZWxzhI/NCsIwEITvgu8Q9m7TehCRpr2I4FX0AdZk2wbbJGTj39ubi6AgeJtl2G9m6vYx
jeJGka13CqqiBEFOe2Ndr+B03C3WIDihMzh6RwqexNA281l9oBFTfuLBBhaZ4ljBkFLYSMl6oAm5
8IFcdjofJ0z5jL0MqC/Yk1yW5UrGTwY0X0yxNwri3lQgjs+Qk/+zfddZTVuvrxO59CNCmoj3vCwj
MfaUFOjRhrPHaN4Wv0VV5OYgm1p+LW1eAAAA//8DAFBLAwQUAAYACAAAACEAN2QPtgcEAAABCgAA
HwAAAGNsaXBib2FyZC9kcmF3aW5ncy9kcmF3aW5nMS54bWzUVttu4zYQfS/QfyD4rliy5StWWfgS
LQp4d4M4+YAxRVlEKVIlGdvZov/eIWUldtLdBZq+1DJskjM8nDlzoT58PNaS7LmxQquMJlcxJVwx
XQi1y+jDfR5NKLEOVAFSK57RJ27px+tff/kAs52BphKMIIKyM8ho5Vwz6/Usq3gN9ko3XKGs1KYG
h1Oz6xUGDohcy14/jke9GoSi1y9QK3BAHo34F1BSs995sQS1B4uQks3OV042SvZ+ZJip/SfTbJpb
4y1nX/a3hogio8icghopor2T4KSG096rXbsXgGNpaq+vy5IcMzoYJTF+KXnK6DgZT+I0bvH40RGG
Ckk8SNNkSAlDjeFgOh6eFFj19ScQrLr5MQia2ZqDgzMTbeMNVPu3PvcHndP33r6FPhJc6vz3+sQd
cRXNDnG2zRrjZInSywrUjs+N0YeKQ2G9RksUMtoeFEjrzrQea3v4rAtkGB6dDnj/EXnPfsOsMdZ9
4romfpBRw5kLJ8F+bV1rYKcSSNG5kDI4LNXFAmK2K0gMbvUyT1HI7j+n8fRmcjNJo7Q/uonSeLWK
5vkyjUZ5Mh6uBqvlcpX85c9N0lklioIrf0xXaUn6Jo1rwYy2unRXTNc9zCXBeFdtWGtJ/FJrVktR
eDhvkjW77VIasgeZ0Tx8TmE4U+tdmhHSGX155VLST+NFfxrlo8k4SvN0GE3H8SSKk+liOorTabrK
L11aC8Xf7xI5ZHQ67A/b/Pqub3H4vPUNZrVw3BAp6oxOnpVg5rPyRhUhtA6EbMdnVHjzX6jAcHeB
xqHPVk+PO25C7fgiKJ78yhb/MZONxuTCKsfO677iTyk1+sGkaCiptPn2es3rYdBRQskB+25G7R+P
YDgl8jeFxTNNUmwUxIVJOhz3cWLOJdtzCSiGUBl1lLTDpcMZbnlsjNhVeFJXrnOstFycEr+13Xsh
rdu4J8kDO8FDX541mHWAwcFdGIDc4a3CnAnRkWrTML/dNuyWuTbpkniMrJ8Cc66x4GWn62yr26nh
/hfpvAyZ6DE7PYxjF+mGBTnG5BSSEBeD1kpsQBnlKnrY4BX3DX1OcJs/kpclln1b7+grOKGIe2p4
CQybz72ouSVf+IHc6RoUJQ0obVEQ9/EZxYN4iE17iONBnKJUOFblUAuJ/TrB25RVYCwP4Q/0cTgD
v/2M1+NaPFygLhA1PeGmiPtD1CjB2AdgZs+A50aA/AdUb3P7vEYd4MKlrUgiEucZctdr2HKJ2VMQ
fmyEQY60IgU47u86DIjXDVyq4hYM3L2D8CVIsTXiwvg8EOwN98S8peSt8RjW/xPR/Jm3wCXWmOf1
uY08Wr5p7jBLMdJB4PsMDvxV3Xv18hMEp5c1/4Z1Pr/+GwAA//8DAFBLAwQUAAYACAAAACEAkn2H
4B0HAABJIAAAGgAAAGNsaXBib2FyZC90aGVtZS90aGVtZTEueG1s7FlLbxs3EL4X6H9Y7L2xZL1i
I3JgyXLcxC9ESoocKYnaZcxdLkjKjm5FcuqlQIG06KEBeuuhKBqgARr00h9jwEGb/ogOuS9SouIH
XCAobAHG7uw3w+HM7Mzs8M7dZxH1jjEXhMVtv3qr4ns4HrExiYO2/2iw/dlt3xMSxWNEWYzb/gwL
/+7Gp5/cQesjSpIhQ3w8CHGEPRAUi3XU9kMpk/WVFTECMhK3WIJjeDZhPEISbnmwMuboBBaI6Mpq
pdJciRCJ/Q2QKJWgHoV/sRSKMKK8r8RgL0YRrH4wmZAR1tjxUVUhxEx0KfeOEW37IHPMTgb4mfQ9
ioSEB22/ov/8lY07K2g9Y6JyCa/Bt63/Mr6MYXy0qtfkwbBYtF5v1JubhXwNoHIR12v1mr1mIU8D
0GgEO011sWW2Vrv1DGuA0kuH7K3WVq1q4Q35tQWdNxvqZ+E1KJVfX8Bvb3fBihZeg1J8YwHf6Kx1
tmz5GpTimwv4VmVzq96y5GtQSEl8tICuNJq1br7bAjJhdMcJX2vUt1urmfASBdFQRJdaYsJiuSzW
IvSU8W0AKCBFksSenCV4gkYQk11EyZATb5cEIQRegmImgFxZrWxXavBf/er6SnsUrWNkcCu9QBOx
QFL6eGLESSLb/n2Q6huQs7dvT5+/OX3+++mLF6fPf83W1qIsvh0UBybf+5+++efVl97fv/34/uW3
6dLzeGHi3/3y1bs//vyQeNhxaYqz716/e/P67Puv//r5pUP6JkdDEz4gERbePj7xHrIINujQHw/5
5TgGISImx2YcCBQjtYpDfk+GFnp/hihy4DrYtuNjDqnGBbw3fWop3A/5VBKHxAdhZAH3GKMdxp1W
eKDWMsw8mMaBe3E+NXEPETp2rd1FseXl3jSBHEtcIrshttQ8pCiWKMAxlp56xo4wduzuCSGWXffI
iDPBJtJ7QrwOIk6TDMjQiqaSaYdE4JeZS0Hwt2Wbvcdeh1HXrrfwsY2EdwNRh/IDTC0z3kNTiSKX
yAGKqGnwXSRDl5L9GR+ZuJ6Q4OkAU+b1xlgIF88Bh/0aTn8Aacbt9j06i2wkl+TIJXMXMWYit9hR
N0RR4sL2SRya2M/FEYQo8g6ZdMH3mP2GqHvwA4qXuvsxwZa7z88GjyDDmiqVAaKeTLnDl/cws+K3
P6MThF2pZpNHVord5MQZHZ1pYIX2LsYUnaAxxt6jzx0adFhi2bxU+n4IWWUHuwLrPrJjVd3HWGBP
NzeLeXKXCCtk+zhgS/TZm80lnhmKI8SXSd4Hr5s270Gpi1wBcEBHRyZwn0C/B/HiNMqBABlGcC+V
ehgiq4Cpe+GO1xm3/HeRdwzey6eWGhd4L4EHX5oHErvJ80HbDBC1FigDZoCgy3ClW2Cx3F+yqOKq
2aZOvon90pZugO7IanoiEp/bAc31Po3/rveBDuPsh1eOl+16+h23YCtZXbLTWZZMdub6m2W4+a6m
y/iYfPxNzRaaxocY6shixrrpaW56Gv9/39Mse59vOpll/cZNJ+NDh3HTyWTDlevpZMrmBfoaNfBI
Bz167BMtnfpMCKV9OaN4V+jBj4DvmfE2EBWfnm7iYgqYhHCpyhwsYOECjjSPx5n8gsiwH6IEpkNV
XwkJRCY6EF7CBAyNNNkpW+HpNNpj43TYWa2qwWZaWQWSJb3SKOgwqJIputkqB3iFeK1toAetuQKK
9zJKGIvZStQcSrRyojKSHuuC0RxK6J1dixZrDi1uK/G5qxa0ANUKr8AHtwef6W2/UQcWYIJ5HDTn
Y+Wn1NW5d7Uzr9PTy4xpRQA02HkElJ5eU7ou3Z7aXRpqF/C0pYQRbrYS2jK6wRMhfAZn0amoF1Hj
sr5eK11qqadModeD0CrVaN3+kBZX9TXwzecGGpuZgsbeSdtv1hoQMiOUtP0JDI3hMkogdoT65kI0
gOOWkeTpC3+VzJJwIbeQCFOD66STZoOISMw9SqK2r7ZfuIHGOodo3aqrkBA+WuXWIK18bMqB020n
48kEj6TpdoOiLJ3eQoZPc4XzqWa/Olhxsim4ux+OT7whnfKHCEKs0aoqA46JgLODamrNMYHDsCKR
lfE3V5iytGueRukYSumIJiHKKoqZzFO4TuWFOvqusIFxl+0ZDGqYJCuEw0AVWNOoVjUtqkaqw9Kq
ez6TspyRNMuaaWUVVTXdWcxaIS8Dc7a8WpE3tMpNDDnNrPBp6p5PuWt5rpvrE4oqAQYv7Oeouhco
CIZq5WKWakrjxTSscnZGtWtHvsFzVLtIkTCyfjMXO2e3okY4lwPilSo/8M1HLZAmeV+pLe062N5D
iTcMqm0fDpdhOPgMruB42gfaqqKtKhpcwZkzlIv0oLjtZxc5BZ6nlAJTyym1HFPPKfWc0sgpjZzS
zClN39MnqnCKrw5TfS8/MIUalh2wZr2Fffq/8S8AAAD//wMAUEsDBBQABgAIAAAAIQCcZkZBuwAA
ACQBAAAqAAAAY2xpcGJvYXJkL2RyYXdpbmdzL19yZWxzL2RyYXdpbmcxLnhtbC5yZWxzhI/NCsIw
EITvgu8Q9m7SehCRJr2I0KvUBwjJNi02PyRR7Nsb6EVB8LIws+w3s037sjN5YkyTdxxqWgFBp7ye
nOFw6y+7I5CUpdNy9g45LJigFdtNc8VZ5nKUxikkUigucRhzDifGkhrRykR9QFc2g49W5iKjYUGq
uzTI9lV1YPGTAeKLSTrNIXa6BtIvoST/Z/thmBSevXpYdPlHBMulFxagjAYzB0pXZ501LV2BiYZ9
/SbeAAAA//8DAFBLAQItABQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAAAAAAAAAAAAAAAAAAABb
Q29udGVudF9UeXBlc10ueG1sUEsBAi0AFAAGAAgAAAAhAK0wP/HBAAAAMgEAAAsAAAAAAAAAAAAA
AAAANgEAAF9yZWxzLy5yZWxzUEsBAi0AFAAGAAgAAAAhADdkD7YHBAAAAQoAAB8AAAAAAAAAAAAA
AAAAIAIAAGNsaXBib2FyZC9kcmF3aW5ncy9kcmF3aW5nMS54bWxQSwECLQAUAAYACAAAACEAkn2H
4B0HAABJIAAAGgAAAAAAAAAAAAAAAABkBgAAY2xpcGJvYXJkL3RoZW1lL3RoZW1lMS54bWxQSwEC
LQAUAAYACAAAACEAnGZGQbsAAAAkAQAAKgAAAAAAAAAAAAAAAAC5DQAAY2xpcGJvYXJkL2RyYXdp
bmdzL19yZWxzL2RyYXdpbmcxLnhtbC5yZWxzUEsFBgAAAAAFAAUAZwEAALwOAAAAAA==
" filled="f" stroked="f">
 <v:textbox style='mso-fit-shape-to-text:t'/>
</v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>&nbsp;</p><p><img src="data:image/png;base64,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" alt="" width="690" height="289" vspace="0" hspace="0" border="0" style="width:690px;height:289px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>&nbsp;</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shape id="Text_x0020_Box_x0020_24"
 o:spid="_x0000_s1030" type="#_x0000_t202" style='position:absolute;left:0;
 text-align:left;margin-left:176.8pt;margin-top:3pt;width:63.15pt;height:43.6pt;
 z-index:251659264;visibility:visible;mso-wrap-style:square;
 mso-width-percent:0;mso-height-percent:200;mso-wrap-distance-left:9pt;
 mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:text;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:200;
 mso-width-relative:margin;mso-height-relative:margin;v-text-anchor:top'
 o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" stroked="f">
 <v:textbox style='mso-fit-shape-to-text:t'/>
</v:shape><![endif]--></p><p>&nbsp;<p>&nbsp;</p></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Figure A</strong></p><p><strong>Step 2: Select the Injection Site and Prepare the Syringe</strong></p><p>Prepare and clean two injection sites, one for each of the two injections. See Figure B.</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:655px"><tbody><tr><td style="vertical-align:top"><p><img src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAXoAAAFsCAYAAADCL3IWAAAAAXNSR0IArs4c6QAAAARnQU1BAACxjwv8YQUAAAAJcEhZcwAADsMAAA7DAcdvqGQAAF4kSURBVHhe7Z0HmBRV9rf/n3kVwyoGzAkU42JY2dU1BwwoJhRBkbCKGSNmTKioCJhFRQHBvAKiIqICKlmBgRnCkHNGBAV13fr6PXMvFE11d1V31XRN93mf5z4zfbv6dnVV969unXvC/zmKoihKQaNCryiKUuCo0CuKohQ4KvSKoigFjgq9oihKgaNCryiKUuCo0CuKohQ4KvSKoigFjgq9oihKgaNCryiKUuCo0CuKohQ4KvSKoigFjgq9oihKgaNCryiKUuCo0CuKohQ4KvSKoigFjgq9oihKgaNCryiKUuCo0CuKohQ4KvSKoigFjgq9oihKgaNCryiKUuCo0CuKohQ4KvSKoigFjgq9oihKgaNCryiKUuCo0CuKohQ4KvSKoigFjgq9oihKgaNCryiKUuCo0BcJ//vf/5y2bds6bdq0cX799VfTWzn897//de677z5pa9asMb2KolQWKvRFAuK+1157Odtss40ze/Zs01s5LF++3Nl1112d6tWrO/Pnzze9iqJUFir0RcIvv/ziHHDAAc52223nzJo1y/RWDkuXLpWLTI0aNVToFSUPqNAXCT///LOz3377OX/9618rfUavQq8o+UWFvkhYsGCBs+eee0qrbLHFbMRFplq1apV+kVEURYW+aBg3bpyzww47OHXq1BGbeWXCQvDf/vY35//+7/+csrIy06soSmWhQl8kfPDBB87/+3//z7n00kud33//3fRWHpdffrkI/XvvvWd6FEWpLFToiwBm1LfeeqsI7RNPPGF6K5cXX3xR3r9FixamR1GUykKFvgjAPs9iKDbykSNHmt7KBZMN788agdrpFaVyUaEvAtq1ayez6XPPPVeCl/IB5qJGjRrJftxzzz2mV1GUykCFvsAZMWKEs+OOOzpbbbWVM2jQINObH4YPHy4BW8zs870vilJMqNAXMOXl5c6RRx4ps+g77rjD+fPPP80z+eP++++X/TnssMOciRMnml5FUaJEhb5AwSZ+7LHHrjPZrFy50jyTX1atWuU0aNBA9ouL0Pjx480ziqJEhQp9AfLJJ59IugPE9Mwzz3Tmzp1rnokHS5Yscc4++2zZPwKpPvzwQ/EMUhQlGlToCwgEvXXr1s7mm28uIsri56JFi8yz8YK0CFdffbXsJ/79N954Y6Xn4FGUYkGFvgAgpUHnzp2dAw88UIRzp512cp5++unYpwT+7bffZL932WUX2e999tnHeeaZZ5w5c+aYLRRFCQMV+irMpEmTnIceesipXbu2CCXtoosuypuvfLaMHTtWInbtZ8DsRO780tJSs4WiKLmgQl+FwGtm6tSpkkaABU3cJhHGLbfc0qlXr57z6aefyiy5KoKf/Zdffumcc845ztZbby2fi0yb559/vtOzZ0/53PmKAVCUqo4KfcxBAEePHu107NjRadiwoRTwsDNfhPCaa65xBgwYUFCLmV9//bXTqlUrKVRiPyuf++KLL3aeffZZuWPJR74eRamqqNDHiLVr1zozZsxwhg4dKrlhmjRp4tSsWVOCjKzg7bHHHuKx8vrrrxd8KgHWHrp27SqzelIn2GPAjJ/1CBabX3jhBefbb791pk+frmUKFSUFKvR5hFnphAkTnO7du0tAE2YLFiStoNl26KGHOjfccIPTo0cPZ/LkyebVxcWUKVOcXr16iXfOEUccsdExIpfPWWed5dx2221Ot27dnJKSkiprxlKUsFGhrySo8EQkKGaW9u3bixli//3332C2bgXr+OOPF2HnAoCwxyXYKS5wPIj6tcL/r3/9y9l77703OI4c13333de58MILJWPnF198IUFkeiyVYkSFPiJYOEWkMT1gbz7xxBM3sDnT8B/HYwYTDbZnFlNZdFSCM23aNKd///5Op06dnKZNm8pd0KabbrrB8cbtlIsC56NLly4i/HFIC6EoUaNCHyJ4hbBQ+PDDDzvHHHPMBrN1gphq1aol5oU2bdo4H330kdiVmemr2IQLC9Mc15kzZzoff/yxZMvEK4njv8UWW6w7J9j6ScPw4IMPyrrIH3/8YUZQlMJChT4kEPhLLrlEskRaIcHeftVVVzkvv/yy88033zjz5s0zWyv5gOM/ePBg55VXXnGaNWsmpjN7rjbbbDMxpyH4ilJoqNDnCLNHPD+sTzvicfPNN4ugMKvUHC7xhfODsFN9C+8mzh8plDH/qPumUkio0OcIIfybbLKJNDxnsBUrVQ/y7Nx1111iYuNcPvnkk+YZRan6qNDnAHZ27LzY4t944w3Tq1RliMLlfGLK0ULmSqGgQp8lzABJscvtPgnElMKBuzTOKy6b5BNSlKqOCn0WEIF5xRVXiBhcdtll6jVTYHA+Wazl/F5wwQVqr1eqPCr0WfD222+Lmx4LrzrjK0xIlWy9ctQsp1R1VOgDQn4ZG4VJ5KpSuGCjJzMoEbZ6QVeqMir0AcBV8t///reIPHnfNcCmsCHJ3JVXXinnu3Hjxuoqq1RZVOgD0Lt3bzHZ7L777jrDKxKIriVzJi6X6oWjVFVU6H1CcE2dOnVkdvfcc8+ZXqUYeO211+S8/+1vf3MWLFhgehWl6qBC7xMyTvJjJzkZt/RK8fDrr79KDQDOP3mMFKWqoULvA5KPsSBHHhvS3SrFx3fffSdmOwqZa4ZRpaqhQu8DQuOZzeE7rwtyxQnnnbKNfA/Iga+xE0pVQoU+A+SuIY88s/kff/zR9CrFCOefGT21esePH296FSX+qNBn4M4775RZXMuWLXU2r0jREjurV5Sqggp9GrDNExy1/fbbO8OGDTO9SjFTWloqiex23nlnzVSqVBlU6NPQoUMHmb1deumlOptXBGzzzZs3l+8FlakUpSqgQp+CX375xTnkkEOkruuXX35pehXFcb7++muZ1VPvV/3qlaqACn0KPvzwQ4mGrFu3rvPbb7+ZXkVxJJvlqaeeKrP6d955x/QqSnxRofeAIt+kH+aH/NJLL5leRVnPW2+9Jd8Pio6rWU+JOyr0HkycONHZYYcdnD322EODYxRPFi9e7Oy2225SjUpdLZW4o0LvwfPPPy+zNc1YqKSC78UNN9wg35PHHnvM9CpKPFGh9+Bf//qX/ID79u1rehRlY/r16ydpEch/tGrVKtOrKPFDhT6JsrIyZ9ttt5XUtEuXLjW92TNjxgzJj6MLuvGAhVS8qIiRyJXly5eLZxaFxDVqWokzKvRJkIKY2TyRsGHkM7E+1z169DA9Sj7p2bOnnA/y1oRhlrP5b5599lnToyjxQ4XeBRWjCI7Cdx5BCAPGYbxDDz3UWbFihelV8sGiRYskpzwz8G7dupne3MB8g9CfdtpppkdR4ocKvQvqwe6zzz7OrrvuGloFKXLXW5/rjh07ml4lH7zwwgtyHk455RRn9erVpjc3CJjacccdJdnZvHnzTK+ixAsVeheDBw8WITjppJNCTUP76aefOptvvrlTq1YtFYM8sWzZMqdmzZrOpptu6nz22WemN3dYe6lfv74E13300UemV1HihQq9i6efflqEnoyVYYJJiMAaxsZ1U6l8OnfuLMf/jDPOCH1h/NFHH5WxNfeNEldU6F1QWIQfbMdOzzllEyc74yeUOqVlk5wp5VOdWbNmO4sWLXZ+/nlVVkLx+eefy2wSWz31Z5XKY8mSJc7hhx8urpB9+vQxvcHABPfTTyudBQsXOTNnznKmTJkq341JU8qdTp2fl3UY1nfw6lGUuKFC7wJ/aIT+3ffed8aOG++M/mHMBm3U6B/lb2nZRGfGjFnOypUrzSszQ91R/PMRe82PUrmQt4jzevzxx8t58AvmO1wop02fkbjol23wHbBt3PhSp1v3Hs5WW/1FTH5BvhOKUlmo0Ls46qijRBD69O3njCuZ4Pzw41jPZn/wP44Z55SXT3NWr/7FjJCeV155RWZ+F198sc78KglcKG1h765du5rezPyUEOyJkybL+bbinvw9oPE9+fCj3pIy4+ijjw4l9kJRwkaF3gWLdZtssqnzef8BMqP3+mEnt1GjE7O6xLZLli4zo6Rmzpw5zu677+5Uq1bNmTx5sulVomTs2LHOdtttJ3mL/KYUnj9/oVzEU4m7u/E96fvJp85O1atL8BQunIoSN1ToDcz8cK38y1/+4nwxYKBvoadVCMI4Z9my5Wa01Fx99dUyu3zmmWdMjxIlLJByvG+55RbTkxq+A/PnL5DzOfoH73Od3PieMDHYddfdnAMOOEC9qpRYokJvoNAIaQ+2334H58uBXwcSehriUDK+1FmzJr0NuH///iI8//jHP8QbR4kOAtQIkOLi7ad4zMqVP/ueyds2ZmyJM/Crb5zdE3cM3DXMmjXLjKYo8UGF3sCiW40aNeQWnB9uUKGnjUoIxKzZc8yI3mDDxfOGCkWDBg0yvUoUkGOIi+qxxx7rw1Pqf+JdhSnO69ymalwYvh863Nl3332dnXbaKZQcOooSNir0Buy3RMTWqLGb8/XXg7ISejurp3BJOu655x4RoNtvv930KFHQtGlTOc5PPfWU6UkN3jhjEqLtdV7TNYR+xMgfnP33P1DWXsrLy82IihIfVOgNZJlkRnbggQc6g4d8J7fkXj/sTI3XZUpZO3r0aMmQuddeeznz5883vUqYzJw5UwqDcJz9iO+SJUs9z2emhtCzPlOzZi3x0w8rdYaihIkKvYEfKC5ytWsf4gz59vushZ6WaVGWRb8LLrhAZpuPP/646VXChGySHN8mTZpkvMMCuwjrdT4zNVwsDzr4YHGdLS0tNSMWJhzT5Na+fXvzbAWZnlcqHxV6w7hx48QN7/AjjnS+/W5oTkLP7DAT1vsGc9GECRNMrxIGLIjuvffecnyvvPJKXzELc+fOy1roJ5ROdI444gh5v5KSEjNi4ULAH58VL6NUcQNsw/PTpk0zPUo+UaE3jBw5Uup/HnXU0bK4lq3QcyvPwm46vv/+e2f77beXHwtNZzzhYktB0rbcckvnm2++Mc+kBt/5bIV+/ISJ4kXF+40ZM8aMWNjwWc866yzzaGO+/fbbtM8rlYsKvYEv5lZbbeXUrVvXGTpsRE5Cny6XDWYEW6yCkHy8b4io1FJ04YB3jRXdM888U/5edtll5tnULF6cnY2eRnqEE088Sd5r2LBhZsTCJqjQk8H1uuuukz6C2I455ph1Y/AYmP0TPc6dAK+/9957nb/+9a/SvCZDjMm2jMNfm1qEu4zkcdiGvlQwvh2L9+M1FvbL7gtjs8/8z/szJp+F17v3x76e97d9vC5fkdMq9IavvvpKUgmfcsqpzoiRo80im/cPO1VjRoi3zpo1a82oG2OjY1n4pfwcIk+KW2b5Su589913cmdGEjNElzzxLMpmMiGQsCybc05D6E877XT5MX/99ddmxMLGClcq3EKPuPEYcUQUEXweI46MgxACgm9FmYszwo142ouCO0cU/9PPeWV8xmQbxqXPjk0/Y7AvXhcLYCz7WrCv5XXAfrE/9FlB570ReRr9jG9fb/t4b3tx4Tn67OPKRoXeQI7yTTfdJHHC6jkjR/2QtdCT8TJdibp333133RcDj5s77rhDHvuJ3FQyYyNh27RpI3dPjRs3lsevvvqq2cKbtWt/y/ouDqE/q15FPp0wc93HGfsdTgXClvw8jxFIN1ZUrYhbQbQiCwg5Fwl7QQAeuy/ebMPr7N2bHcd9cUgF4st4FjuW+8Jg9zN5wmDfx70tpOpLd8yiRIXe8J///EdOxHnn1RfBzlbop5SnnznaVMjkvqcMHe9LaTtmoD/99JPZSskGTGYER2GXHzhwoPSRyAxvGAQg3aIsF2ebodLr3KZrvK5+/fPlvHI+i4FMopVK6JP7mC0zlhVFK5z8dWNn1GC38Wr2YpBqnHQg8Ii+NbV4CX0y9n1U6KsIdqbd4MIL5cebrdDPmZs61wlVjoigxLRAUjOEntqlpC9GnAYMGGC2VLIBUxjnkORia9askT786XfeeWenevXqGWMWpk6dnrXQX3FFxZ1Dr169zGiFTSbRQgD9CD0wViahdwut3SYdqcZJhZ3VYzpi1u7eJ3C/vxv7Pl6i7tWnQp9nEFxOxKUNG4rIZyP0pLNdmsaHnttR1gGoIYsQES7PDPDaa6+V927btq3ZUsmGdu3ayXG8+eabTU8FtmYvxV/SMXfefDmHXufWqyHwFB8pT1wgmrdoKe/RvXt3M1phw2dNNsO4QQCxUbvxEvpkM0kqgba2e7DbuM07FtuXahwveG9E3i4Kg3ufgP/t+7ux7+Ml6l59KvR5BhsuJ6Lp1c0kACYboec16XLTW/uxLTmHpw3JtgjRZ0aPFw7J1ZTgYHo5+eST5fgm3xnZH+mtt95qerxZvnyFL6HnPLOO8/IrrzrtHn/SeerpDrKIz3s0a9ZMZvVxaj179pS1gzBrINgFUoTaC/dCpMVL6O1CqLV9pxJozCnuCwfCzD64398uwkIQoffaL17rFmr7HUpGhb6K8dxzz8mJuOaaVomZ2kTPH3i6xi0/gTOpkmch4Jxk7PGffPKJ9CFOvXv3lpkmKZIJoZ86dao8pwQDUxjBZ6SVwLPJzdChQ8VOf9xxx6WNkl2dOEdjx5YkzqX3ObaNRVuC6mofcqh8Z6pCozA92TzDgpkz4yK2bjG1HirJIgx8/3mNvQAgzAi4dUUEK5y83oo/gpm8+MoYbGfNLTTGsu9pn7eLs+lgGzuj5/X2tVxYrFjbNYLki5e9ULk/g113cL8349LndVwqAxV6A7NqTsT1N9wogu31A0/XEPry8qlSfs4LxIcUC6SydRenIJkaQk/VKd7/rbfeMs8oQWDmyvHzqtuKbR4RwE6fLkUBF2nKRGay0zOjHz58pHNL69ucSy651GnY8DKnTp2K6mR16tQRU1zLli1j01q0aOE89NBDgcoo+gFRtiLJZ6chZIijl5gh9JwHK/i8LnnWa4XePS7bu80qFkSX8ZK3YUz6bOO5dPA6Ow6Czb7zOejjObu/ttl99nqf5D6a/UzuVtmo0BseeeQROQGtW98qhcG9fuDpGrf8FBBPhU2Ze8YZZ5ieChYvXiw1Te0dBakRlGBwZ3TbbbfJ8cObKRny/jds2FBm9enc7RiH0pB+7fSY+MhWOnFSufNg24fk/R944AEzmpIMQphJdK0o8lcJDxV6A1dyvmBt2tyT+OFO8fxhp2vMAhcuTF1GDgFgfC4oXhA6j+mGQhlqpw/G6tWrJRqWdY4hQ4aY3g2xMy3869MxM3GxDrIgy+yeRdlHHq1YCM60DlDMqNDnDxV6g50Rtm37cFYzen7wK1ak9oM//fSKyEkicL3AnIMvPberuAkq/iGJGVWkSGSWKv0EC7TW4ymdCYOLdVAXS2b1T7avMP21atXKjKS4wRzCdzuTjdpekP0EOin+UaE3XH/99fIFe7TdE+Iy5/WDTtVGJxqpD1IJyMKFC2WxFRs9ee+9wLZvg6mwNyv+sQuD5557runZGMSFVAhkKE1XJBzPmx/GeJ/nVA2h79ixk+wD2TKVDfGyUXvN2Jntu7fJNPtX/KNCb2jevLl8uZ548qngQp+YASL0qWrAkv+EhGm4/6VLXvbkk0/KPlCBSvGPdVt99NFHTY83J51UkXhs8ODBpmdjMANxd+Z1nlM1hP7119+QsVlUV5S4oUKfgEW4yy+/XH6oHTt1dsYH9LpB6EtKJsg4Xrzwwgsy9k033WR6vKnIt7Opc8455/iocapY6tevL8c3U0DUXXfdJdt5Ldha1qxdGzjnDULfo0eF14/OQpU4okKfAFGl4hNZJF95tYssrnn9oFM1hH5CaZmn0NOH3RYRyJRYy7pg7rnnnqH6PBcyK1eulGLrpJUoKyszvd7g3cR5wAMnFbhmZiP0739QMfYJJ5xgRlKU+KBCn4Db9TPPPMPZYostnTe6dpMfrtcPOlVD6MvKJnkKPYuDRLxiuiGFbjp4PaKFYBAApGQGP2dSPrOQ7Y5P8ILqT3g2HXnkkSnXUzC/jR0XTOhxs+zTt5+cNypNKUrcUKFPwOz5n//8p1Ntm2pOz57vZiX02PW9hH7u3LlSTYpZeqbKU2Aj8IolC2Ku9OnTR/zjL7rooowh/izCHnzwwZLkLFX5xmyF/tNPP3c233wLp2bNmp7fA0XJJyr0CZgJMhNjZti79yeysOr1g07VEPqJk7xn4CNGjAh0S08EI9s/9thjpkdJhy0bePvtt5ue1HAhsCa6vn37mt4NIUVC0PPP9p/3HyAePWQnTVdhTFHygQp9gtmzZ4v7Y43dd3e+GDAwS6GfYkbbkNdff12EKDmTXyree+892V7d9PxBwRaO18svv2x60mMLvXTu3Nn0bAhurtkI/cCvvpE8OzVq7LZRrh1FyTcq9AmmTJniVKtWzdn/gAOcYcNHBnavQ+gnT/YWeiIx0wlLMpS/Y/sTTzxRTQAZYIaOxw2eSn4rO3FB4PimimD988//OSXjJ8g59TrXXo3F28FDvnMOOfQwZ4cdtvfMy6Io+USFPsEPP/wgP/6jjjoqsMcNDVEon+pdWapRo0YyNrZkP0yaNMnZcccdpXhGughCpcLjhkXYbbfdNqPHjcXa9El+5hX3wMWVpHZBhX74iFHOySefItlJ+/fvb0ZTlHigQp+AHz9ifPbZ52aduXLmTO+EZszMGXvkyJGmJz1kWsTzhpS7fsWrWCEhHAvdRLymC0RzM3z4cEmXQFUvr5xCCP3kyeWBhJ47QMw3DS+riMV48803zWiKEg9U6BN06NBBfqDXXHNtVjN6kmDNX7Cxax8zRhZ5ybHiV7QRn9NOO03cANNFcCoVJjfOWxCXRqp6kXPloIMOShmrMGPmrEBCTyM/0s23tJb9efjhh81IihIPVOgTsFDKD/SRRx8L7FpJQxR++mmlGW09S5YscQ488EBnl112EYHxAzNKG6X78ccfm17FC1JLcJzS5bhJBnMPd0t4WHFH4MWiRH+QDJY07gTbtXtC9of877q+osQJFfoEtgRd9x5vZ+VDPyFxF+CVsoBqUbvvvrvMHjMVpnZDzVP2B48dJTU9evSQ40ShjyBQUAIXS2IcvKAcZODo2MR34I2ub0nQHRky/ZqSFKUyKHqhp0g3P3wiVz/7/IvArnXM/GbP8RYM0g1jJqCEnZ9gKQs+9AjY448/bnoUL8hZw3Ei9iAIxx57rLwulTkNz5up06YHmtXzveH7QxUrfOmDXNgVJWqKXugnTpwoYnxgzZrOoMHfBhJ6mc0nbtlTRWQOGjRIimGceeaZgYqJdOnSRYQIH3ElNdYn3q8PvaVevXryunTFLZjV813wa6u3Lrk1ax0kdwt8rxQlLhS90FOoGz/sU089zRk+YrRvH3pme+MnlDo//5z6Fr1fv37iynfJJZekLUqdzEcffSRC1KRJE7X1pqFp06ZynDheQbAur7ZIeyqWLlvujB073vfMnqLyp51+hoxNjnxFiQtFL/TPPvus/DCbN28pHjeZhJ4fPdtMmzZDzD7pePfdd2XsZs2amR5/fPPNN5qu2AfnnXeeHF/unIJgi8x0797d9KRmVeJCPnlKuZz7TLP7kvFlTqvrKsZ+4oknzAiKkn+KXujtj57izsklBPlh0+yMjlv5qQmB/2nlSl8z7a5du8rYN954o+nxB7Z9TD4kWgu7cn8hYWMUyCcUhLvvvlteR50AP3A3tmz5CmfKlKmySGu/E/b7Yb8vLOQ/06Fi4tC4cWPzakXJP0Ut9KQnxmcdP/cur70uWQj5AVf8iBM/3MTjSZOmONOnz3QWL17irF0bbHZtC44gLEHAW4eUDAROqfeGN8QoUH+USNSgKQeYbXNegi52c23/NXEXt2DBImfa9BkyMRg7riJdAt8ZJgLkpcdcR5H3IOY6RYmSohZ63OtIREVk5ajRPzgLFy12FiUaHjJkIGQ27RUm7xdbGjBoJkpqzFKAhERr+H0rG8P5IVCKjJFBI4ife+45OS/33nuv6ckOFuF/+eXXxDn6Wez5S5cuk4vO7rvv4dSoUUOS5SlKHChqoR8zZoz84I8++uhIFj0feOABGZ91gCBwp4GbHkE9WmnKG4KdiE8g+Km8vNz0+sOa1KLwasK76owzKGKzhTNw4EDTqyj5paiF/p133pEffFQpgbN1/+MuAgGjPN6yZctMr+KGVMD777+/3PXMnDnT9Prjgw8+kPNCBGvYMGFgTSab864oUVHUQn/nnXfKDzLojNsvdqH3rbfeMj3+ICc6QTfYekmjoGzMtGnTxOxWq1atwPnfcXvlvOBmGQUvvviijK9xEEpcKGqhJ5CJHyQ5U8KGmR0zRsbHzTIIvBazBK+dN2+e6VXcUFMXOzgL1kGjUG2OnAYNGpiecBkwYICYbjDhqNeUEgeKVuixg++3336Ssjborb8fmJXjYoegBE1OhtDbIuGzZs0yvYobFmAxb5GPnsXrIHz//fdybM8++2zTEy7cYbDAT54j6tQqSr4pWqGn2AgeG3Xq1AmUh8Yv2NkpboGgYCoIggp9ZkpKSmTBmoX0oAVayEnPsT3llFNMT7hwkaeIDaY39lNR8k3RCn2vXr3kx06agSj8nYloPf/888XPO6j3BUKPHzb7h0+9sjG5CP2oUaPk2FJ8JCquvvpqeY+3337b9ChK/ihaoW/btq38ENu1a2d6wmXt2rWSJx2hD7oGgNDjI87+seiobEwuQm9LRxJ5HBWdOnWS97j99ttNj6Lkj6IUemtW4dYaV7soIA8Oi3GkMvjuu+9Mrz/UdJOZ0tJSsdEfeeSRzqJFG1f3SgfxE2SYrFu3rhzrKKA6GOePyGtFyTdFKfTMAFnEIz3xuHHjTG+45CL02HjJkc+FKOhCY1gggJi0/vgj0X7/Q6JAbeNCST/PRyWUmaCM4B577CFF1IN63XDOSXtBXvpcIp/TwZ0Ya0BUGNOgNyXfFKXQ8yOk0EjNmjUD5YkPQq5Cj+sgr62MgKnfE0K+atXqxHstd+YvWOjMmj1HcrmQtZF8LuTcJ7OnbaWJx/TzPFk82Z7XkQKA3DyMFzWkF8Brihb0rqcyhJ7zhlmJ4uWjR482vYqSH4pS6K0f9VlnnWV6wocLCNkVt956a1n8CwJ5XEh/sPPOO0cyG2RWTh79efPmJ8R6qoi3Lbhik7qNGl2RmTFTG0Uzr7EZPhlv8uRyGX9l4rP8lni/sCGQ7OCDD5Z6vEFTIFSG0HO3Q+1f7sref/9906so+aEohd4mtYpyoQw//RNOOEHSGLD4FwRmq9z2c8eB6IcBwrN8+Qpn5qzZUuPWS7Rtut1cmte4FGiZMXOW3DGEJawEIuEaSxzE+PHjTa8/KkPoweY6IrmdouSTohR6m4skyuLbCP3xxx8vQk9++SAgRAgYtWZzjazEhDRv/gIxv1AwhZk34usl0lE13q9ixj9O9mPO3HmS7jdXuJByHoPeMbGQy3nBhTXKyNU333xT9o/i5flay1AUKEqhv+CCC+QHGGV2wZ9++sk57LDDJN0wC4dB+Oqrr8QrBPdMzCzZ8Ouva8R2jiklH+KeqlnRZ79mzZojaX6zxVaYCuq+yvnALFa7du3ArplB6N+/v1QKI55CK4Up+aQohd5WJgo60w4CaXSxHxMKH3RB1ZYgJOgm6EyQCwO28YoiKphOvAU3Dg37/riE4M+eMzcrO37Lli3lOJGFNAjUISAZ2p577hnYvh8EInBZoznppJPkDk9R8kVRCj3h6QhE0IIVQZgxY4bMyhGUoGLduXNn2b+glalWrPjJKS2bKLPmuMzgMzU7w8ekgw0/CNYG3qFDB9PjD4q52PWTYcOGmd7wYe0ArxsqYXGHpyj5ouiEHtdFfK9ZjAtqUgkCBb4RoXr16pke/7Rp00Zey6KxH1honT17rtjgwxZ4e9EQQXb9T/PaPttmx8Pc5HeB9JVXXpHjdOutt5oef3Dhveyyy+S1//nPf0xv+ODGS/QuJiKtK6Dkk6ITem6h8WbBq2X69OmmN3xsvdhscpI3bdpUXvvee++ZntSQaqF86jSz2Okton5bsohjRy8rm+RMKZ8mfvXTZ8yUvzwumzhpnUtm8utyaYyBf/5aH4u1Nq88Uc5BsRfTqGoRAJkrMd1RHAVTnqLki6ITemZWBNlgP4+ypqe1H+N5EQSEG/9+FvFYlE0HC64IMbZ4L9EM0hgDu/6UKVMl+IkAKuz93C1wF8Qs2DYe08/zbMf25eVT5fVhiD0XLUxQmYLZMI1wjHGTDArFYHhts2bNApvW/EIMBOsALPxqumIlnxSd0BMuT2UiWlRFPTA9kEcFIRkxYoTp9Qd5W3D745YfN8tUrFmztkLkcxRWRBWBnps4FqtX5xYljDDjylkyvjTnOwwuGPj74x6aCtJD4IaKmKbbzguiVYk85lhHtVDKPjGb33bbbWUBWFHyRdEJPYukFITAfBNVHhmqH3HLTjnAoHcNrBtwt0GFqVT7x4Vk0uQpOc2eee2Pib8zZs5O3EWE6/qHKyGuk7muGXARmzhpckrXRBY4iY7FhTWo94wVYdZq+E5EAXc91LXlghLl3aOiZKLohB4hJesh2SGjsptSUQqPG/yng/rBjxw5Ul5LCl2vRUnMDES35jKTH51oY8aWOEuWROdDDuS+wY6fk9gn7gymT5/paV5BrCkHSSroTGYuLy6++GK56/KzFpItTCh4jyiqmCmKX4pO6ImKxCxCetuogmXuu+8++XE//PDDpsc/ffv2ldc2bNjQ9GwILoheghikIfLLKymjIi6fvJ/XfvhtXCgWp7gotWrVSo7XG2+8YXr88/zzz8trr7vuOtMTPgTN8R5RLvwrSiaKTujHjh0r6YlZwIuihCCzTHy0MQl8+eWXptc/+IQjDPfee6/pWQ+pgfE3z9Vks2BBMJMVs2miiO+//37n008/Nb3+Wbhwsee++G3M6rHXe5lw2rdvL8frwQcfND3+wYeeuwG+C1HZ6W2lMC0go+STohN6omGx6bJYGkVmSH7QW2yxhbP33ntLyt6gXHPNNSIMXt46CGauIo/N+7+JC0YQuAtizYH9wt7ctWtX84w/8NLhfXPZd8R+/vyNL1BExbJfV111VWDvGUx33NmxWEoUaxTYRfkJEyaYHkWpfIpO6PGC4YdNvVAiJMPmtddekx/2FVdcYXqCcfLJJ8vrhw4danoqYDY/cVLuC7C4QgaFRc/HH39cxJT1A0L6g+bxX7hwUc77PqG0TBY43QwZMkRqC3Dcgmb65MLw73//W443cQ9RQGI7xg+aYVNRwqTohJ7bdULfEYZsZtzpQDgaNGggP2yKjwcFH3pcBZk1J/tdr1z5s3jJeImg34YXDDbzbEFUOXYU1Ahq9uJY5yL0NK/9x2MGV1k8aLLxbGEhlpzxJJBLvoiEARMKvg/pXGUVJWpU6EPEig6LvbhYBmXSpElyt0HIfPLslJl4rr7pLIr+9FN2dzFcxFq0aCGixeIl5pggkKUyW6HHcwdff/bf646EXDLY2rMxj2C+wyxVrVq1SOIq8ArimAWtSaAoYVJ0Qv/9999LRsFTTz019AW4t99+W37UF154YVZpafG4YXbJXUGya2X5tOk5z4h5PS6P2cLnQ+yD1mgFBDXo/iPsQ4eNdB54sK3TqtV1zrWJdkvrW8WbyTZMStRl5bgT5dquXbsNns/UHn30UYmU5vWY2x577DHP7bJpjEXtX8bGRBTm2EEbeYGCBpWFCYv45BcKWtWNNS/2nePIwruSHUUn9CQbwzRCsrEwi04ww23SpIn8qLO193bs2FFef9ddd5meCphNEwWbq9BzRzBzZn4Cd/D9D7r/zOS/HjQkIeQVvujasm9RFynnLu/bb781jzYEN2aeYz+yEXouErxWhT57ilbozz777FCFnlkubpu0oMWqLal8whH6sPLIMEvOpdhHNvySOM7jSoIHTmGTHzZ8pPPkk085t99+p3PnnW2cu++5V0rzPf3009JwRyVvP8ftiCOOkMf2OT+N7XHNxHyD+eemm24KPEaqxjikqWbfbr755tDGDdqeeuopye3DGlAUIMZ8xkzxCJjYsqnTbC8SKvTZo0IfErgc8mWkelU2cFvNXYaX/32YQs8YJC6LYuHRC96nvHxaTvtO7hziByg6TqbOZHD/5NjjypgtjRs3ljGCJqHLBN8zxo2yyE2+QeCZ4PA508ULIPIq9PlBhT4ESHOASPNlpDpUNpD0ittr8vAkL+Qi9LkGSrkb40ybNsMzxUKY4K9PUXBMRl77EbSx32UTJ2+UVoJEcDvttJPMypcsWWJ6g/HRRx/J+gheMmEeF1u2Mmi5w6oCZhns51aM083qrdATtGjXLnicfHHgsa0XwAWEbfg/Weh5T+4S7Ha8tzvanRgLuy7Ae9px+Mt2vI/tY3/Yxo37NYzvDmLkvXk/Oxb/pxonDqjQhwCzNb4IuPhla7bB/Y7ZfJ06dTz3ixzwYQk9DfGdnJjZR2XG4TNMKZ8ayT4ne/zgPUVuIDJZJscf+IWYCs4f5psxY8aY3twpdKFHfG0pRyuKqWb1PI8QIpgIJa9le8TaYi8cVrQZy4q5W+ix2/ObYxzgL4/ZltfR6LPia/cREaaPfWE8+x5sw0XBwnb02fFtkRu7D/TzPO/HvrI/di3BPU5cUKEPAbwpOMGc8Gz55JNPZIyLLrrI9GwIaYTDmhnbRg56Fjznz18Qmv127W+/SQQrNvnw9/dHWdRNBuG3+f+xRWcLi+CMcccdd5ie3ClkoUck3SJthTXV7wBxpbmxYm+FmNcioG68FmPZJjlNiBVj/lp4nPyeXvvBY7a1INZ2nyx8Vi4mFl7j/vzgNXYcUKHPESJEyYTJTDCXH/MTTzwhXzTqoHqB//sPIc6O3Y1Z9/gJpc7s2XOcnxOzY6JwMRf5ge2ww1OAhHKGYZqYvNrSFHVlWXDk+HnlCPILQkWULeczrBTWhSz0CG+yGFrB5CKQjJcIMptmeyviCGnyhcJeQNyzaR4nvzfvSb/7PZIfg9d+8JhtLfyfqtk7Fj/jxAUV+hyx5eyIFs1lgbNRo0YyzgcffGB6NuT33/9wSkNwsUzVGNeOzaInZQNJfrZ02TK5yPz88yoRc/6uTDwmiybPz0hsh7gnjxFFY0E6lf2c2q/Y2C+55JKsbexctE877TQ5D2GlLi5UoUdUEWU+m1dzz74tXsII7u29XptK6N0zdwv97vdIfgxe+8FjtrXwP++TDj/jxAUV+hzAZEA6YU6s30LeXjArJp0tQkV0bCrmzZsfujnEq1nB5r34i5vj2LHjxczD3zGmoAjP24LhXuOE2XivOXNSV2nCrr7jjjtKkrJc6gy8+uqrcj7r168fOPrXi0IVekTXS8ztBYCWPKv3EkY7C7eizf/JNu5UQu9195b8eh57ibFXH9taUo2PGcniZ5y4oEKfAyzYIC54ykydOtX0BgePG7xG9thjD6lpmwqibXE1rAxhTW68p21ez0fZeM9xJaVpIztJGUG1KaKeKS6TLQhPjRo1ZGG8pKTE9GZPIQo9xwgbebKQWxBkPnPyhcBLGDG/sK01hzBu8kUiWejB62LC/2znNunw2EuMvfrY1sLFgvGTPWjcZiU/48QFFfoceOihh+Skklo4l9kffvMIyxlnnJFxUXTRotxSFVfFxuf1k3XT/shyFdXbbrtNxuFvrhSa0COmiJ31bvHCLp4ilG7zB+eHPjsr5jkeu4XZvpbxrfgzs6aP97XCay8Q9LEf7v2yWPu/u4/tuJgkX6jYhm3te1rvHPseXGR4jf08dpzki40dx90XB1Tos4RwcuuOl61Ln4WUCXw5WrdubXpSwzrA1GnTK8WEE4fG5/RyqfQCbxmOY6dOnUxPdthU1uTAydZd1lJoQm8vprYlY2fz7mZn4ognook40o8oui8EFsQeEWUb3g+zDo8ZxwoxuLdjTC4IVmDtXYC7BemzY1jh5n3sBQq8XuPVFxdU6LOENAWczNNPPz3nKNMbb7xRxnr55ZdNT3qY9Uft3RKHxudjYdivr3/37t3lODZv3tz0ZAcBWdT7ZayXXnrJ9GZHodrolapF0Qk9PzgqQJF/PNtsfgTo2DzjuXpn2NQH3BkMGDDA9GZm9epfnJLx4aRFiGPjc7H4G6SYCAuynBP3rXq22Nq9lALMJcZAhV6JA0Un9P3795cqSaQSTg6l9wsuldjUjzrqqKxD7i0sxHJbyAJg0EVEfN5LQsqBE6dGIBeulFS2CgLFWnbeeWdZHCctQi5wt2dv21O5vPpBhV6JA0Un9J9//rkIPRGo2Qr9eeedJz/eZ5991vRkD54dzOaZOWaTw371L7+If32h2Oz5HBQCx2c/KPZOi6CnMOyjXbp0kfOcS0prFXolDqjQBwQBwfRDyb9cZ/PQp08fEQICfbKFCwQLtMzsq+rs3u57+dTpztq12ZnUiEewNWCDFjD3gtTTRMly9xbErOaGO0f2Z+DAgaZHUSofFfoAsOhKFSJ+uI888ojpzQ2bJ4cqQLnw55//cxYuWix27ao2u2d/yZNPpG2uQUrPPPOMHM977rnH9OSGTU3BzDwb7PcFc5+i5IuiE3q7yEZEa9BQeep+7rDDDs7ee+/tlJeXm97cIDCD/SGEPwwo8jFt+kyJZsXW7SWscWnM4NlP7kbCyqLpToWQrWnODTlvWD8hM+aoUaNMr39U6JU4UHRC//HHH8sPj0ITQWeP999/v7z2+uuvNz25c/jhh8uYEydOND3hQH4aCn5YQY2LSce9L/jHr1jBgqu/BGp+IGU0F2PWPMIKWrn77rvlHN1yyy2mxz9XXXWVvJbvnaLki6ITejwo+OHxAwwCbn777ruvLJyOHDnS9OYGXiK77rqrFMzI1UvECy5k7Pf0xAzfVqjKl+DzvphoSF9M0ZOVK3/O2UzjBZ46FHDZbrvtEp97uunNDQKott9+e2f//fd3Zs8OVnPXrhmElSRNUbKh6IS+Z8+e8sPjBxiEDz/8UF6HV0euAVKW7777TjxEGBOPkSj59dc1YsOnGAjmEiv6UYh/8ti83+Qp5c6ChYsiK3TixsY4INBhwGJ3thXEbDAcwVyKki+KTuhtbVeKQPsFYbc1Rf1Gr/rh7bffljGbNWsWyezWC96HIK3Fi5c406bPENdMZvvkumfGTbMC7SXiyc1uy3qAfe24ceNlXMbnfXi/yvp8YGfRPXr0MD25YyOhGzRoYHr8ceedd8rrvFLqKkplUXRCb/PKtGnTxvRkBhPAXnvt5VSvXt2ZMGGC6c2ddu3ayb6E5cGTDVzEiLK1+eWp4FSemPWXmQsA3jBeAs8snecRdO4SZs6cLa9nnNWrV0vxknxh8608+OCDpid3cLXE9k8LYr6xie86dOhgehSl8ik6obfucrg1+oXbdV5D/pMwZ6atWrWSccPw+Q4TPiMXALySKHjy22+/SxoA23hMP8+zXWXO1v1AoW+Oa5MmTUxP7vAZL7/8chmXnPV+6dy5s7yGhXxFyRdFJ/Q2w+GLL75oejJjPSdyTXDlBtc/zACbbrqp89lnn5leJQxGjx4t5wtbfZh069ZNxkXw/brm2jWha6+91vQoSuVTVELP7BO/ZvysWVz1A14rFAQh42VYXhyAd8g///lP8Q4Jy4tHqYBUtlxAKUQS5t0G1b/wqceMN2PGDNObnkGDBonQs5irKPmiqIQe0T7++OOdbbbZxhk+fLjpTQ+h60TSnnDCCVnlokkF7pSE1+NeOXnyZNOrhMGcOXOkYhf55IMmRksHs3hbU5bkeH4oLS2VFApHHHFETlkwFSUXikro8VtnRkZ2Q/73Awt6/LDbtm1resKBxT38vcmZk2txC2VD5s2bJ+eZCOawK/3YxdX77rvP9KSHiw7xF9wVhnlHqChBKCqh59ab2TnRqH5u6TH12KRUvXv3Nr3hoEIfHVzEqf6FuHKcw4Q7PL4PFJzxA3eRJ598ssRLDB482PQqSuVSVEJv89xcfPHFpic9mFcIpccMMG7cONMbDsw6ibTE3hs02lJJD/lpMNtw50a+/zDhIoJocxHxa8pr0aKFfO80aErJF0Ul9Na10q9/NTNtxJjZYdi33Yg7YsFtPcKkhEeUQk+tYNZVuPjzvx9svESuGUoVJVuKSujxq+YH9/7775ue9LCQV7duXWfrrbfOuQB4MlboESQV+nBZvHixU6tWLRHksC/QVAHD/FezZk0x7fmBPDd4euHx5fc1ihImRSX0//jHP0ToSTfsFxtOH2bqA+BuASHijiHsBcNih4IwhxxyiLPLLrs4U6dONb3h8Prrr8v34corrzQ9mSG9MZ5ef//738VmryiVTdEIPT9+RJVb7iCzvF69eslsrH79+qHOxtgH9oWZYZgugMp6oad+bFh1AywUrEHoCYTyy/LlyyVD6Y477hhJllJFyUTRCD21WRFWFleDlADErMLrqlWrFuqiqQp9dCxbtsypU6eOCCt+7GHBOWPxnAtI0NiHww47TC4QYV94FMUPRSP0X375pQSunH322ZJNMQi2StBzzz1nenIHkwJRsURvkgRMCQ9m0EcffbQIfZhJ6Gzm02yqV9mC8lokXMkHRSP0LIjxQ2vatKkUkQ6CTZJFVGRY0Y3M7FjkxcSgEZPhEoXQExVrxfrNN980vf655ppr5LWkplaUyqZohJ6Mg/zQbr31VtPjH8w3CDLmG4qFhIEKfXRYbymqQlFaMAzKysrkjhCXTUxDQXnggQfk+9exY0fToyiVR9EI/TPPPCM/tGxTGdx2223yegpJhAFCT8Fp8t2EmUNHcZyVK1dKTqNtt91WMlmGga0XfMMNN5ieYJCPPpfvn6LkQtEIvc1RguBnw5gxY5wttthCZnRhuENSDBx/7COPPNL0KGERttDjl8+dFxGx2d7RWbfMbO4oFSVXikbo77nnHvmhZbugil3/nHPOkTHCKAunQh8dYQs9dnXOFfltfvnlF9MbDJuX/rrrrjM9ilJ5FI3Qt27dWn5or732mukJDouy+NQTeJVr4IsKfXSEKfQswtpi42+99ZbpDY5d0Kc+sKJUNir0AWAR7thjj3U222wz8eLJBRX66MBd9dRTT5XF7u+//970Zscnn3wi5+mggw7K6eJuE+qFWd5QUfyiQh8QXs84CH4ui6gq9NGBeQUzC4vduXhJccGwhUaClJ70QoVeyScq9AFZtWqVU7t2bRHpXFIXVzWhZ42CiOKqkJQrLKEnJxJBbZxvv4VqUqFCr+QTFfo04G1ByTg8btzYYuG5mG+qmtBjwqBgS58+fUxPfAlL6Pv16yfnmfw2bsaOHSvfiyBZRzluKvRKvigaobd+8H49ZoYNGybChktl9erVnaeeempdRK314OncubM8zoaqJvTWjxw31bgTltD36NFDPrPbU6ZTp06S64bvBekrhgwZYp5Jj43MJhuqolQ2RSP09957r/zQ/LhXYp5o1KiRbH/MMceI//Rf//rXdRGRiD7PPfLII/I4G6qa0Nvjd/fdd5ue+BKW0PNd4TPz2QHzDeUfGfeoo46S58id5AdcNNn++uuvNz2KUnkUjdBT3Ycf2tNPP216UmO9NhB4kqGRN4XX2tzm5Kbn8V133SWPs6GqCf1NN90kn7lVq1amJ76EJfRPPvmkfObHHntMHo8fP15y3CPy3377rTyH/d4PNmCKO0tFqWyKRujtLNxPOTe3ex5CQcpbRNmmKbZZDG+55RZ5nA1VTehtda7LL7/c9MSXsITeRlOTvgBIkIbQU0AEOz3PETHrB3LcsL3fMpaKEiZFI/S4x/FD8zMLdws9NlhmcIgyVaGAIs+MdeONN8rjbKhqQm8zN55xxhnOn3/+aXrjCUKPWyRCn4sfPaLMZ7aJyKzQ41pLsjSe8yv09o6SCYeiVDZFI/RWnP2YHtxCzy36CSecIK8lgyEUm9CTXfOUU06Rz0zhFqJF4wyBTUSzkm105MiRpjc4bdq0kc/80ksvyWNm8RSLITIa11qe8yv05Lhh+y5dupgeRak8ikboe/fuLT+0yy67LKMveLLphgU3XmtFo9iEHv95FqX5zBQ0j3ta5bBSIFiht8FSFIjnO8HdAueP5/wKvTV9kQpBUSqbohF6TDAsrvIjRcjT4RZ6ftyNGzeWH+lnn30mzxeb0M+YMUNSAPCZCSDKJh97ZRKW0FvTzbPPPiuPv/jiC8l1dOGFFzozZ86U5/wKPWsGbM/3SVEqm6IReoQV+yr53zMVaLZCz4Vh+PDhYtfnR0rxEujWrZs8xhMlWyZNmiQ5c4444ojY27ypt0t6Zj7zNttss86EFVfCEvrkxVibgZJqUdzl8L8foSf+Ap97LhJcNBWlsikaoafqEIW4mZFOmzbN9HqDDbpBgwYy4/7888/Xucbdfvvt8jx2VvfjbKhKFaZY0MTezWfecsstnUGDBpln4gnn+rjjjpMKU8lRzUEgToLPbBdQcbPk8RNPPCHpEfiftYBMEGHNJGPXXXcNVJheUcKiaIQeTjrpJPlx+rl9fvzxx2VbUidQ0BnRZ5bP7MwKfS7VpqqS0HOxYzbKZ+Y45Jq5M2rCqhnbvn17+cx8F4B6BBwHjgfnnuf8VIxinYe7Qy4KmcyGihIFRSX0lIHjx+knEyGmFW79CXfHvo+NmsfY6W2hZ4QgWwi+YpZMwM2aNWtMbzzp1auXfF7bsi3eUlmEJfT2gs4aDWKN2apGjRpiDtp///3lsR/TkK1XfO2118beTKcUJkUl9O+++6784FhM8wNFItieEPhHH31U/ifHCX9zFZHp06eLqx7mJEwNcYbFSD7zDjvsIH/JexNnWCxm7YMcRVyws6W0tNTZc8895TNjsuIvKSDs3R4eXL///rvZ2huEvXnz5rK9XeNRlMqmqIQeccVGv9tuuzlz5swxvanBnRI7L7ZVZnQ333yzs++++4oJJ9csjlVJ6DFTYLJggRPBintiLuzgmMSwi9u0FdmCpw3nm/POjHzUqFHy/cEUM3jwYLNVavie7bXXXnKRzGW9QFFyoaiEntnXlVdeKWKFa6Sf3Opsx/a8Dvs8wThh2NSJssUMgAkgzgt0fGZ8wPEQatmypQg+C9U2k2ccYfETUxsXaC6oucL55rzzfSGTJd8HvyUBrS8+d5FxPmZKYVNUQg/YVLG7b7755s4bb7xhelODOxwzOITO+tGHAXlzCD7ab7/9AuU1r2wQN2IPMF2QEI51BRa1f/31V7NF/OB4clxxCZ07d67pzR0W5bHL833A5TQTrG1w3FjbIe21ouSLohN6ICkZQk/qYQpIZMKmqyXnzdKlS01vbsybN09m89zW+zEj5QvKJWIGQeAoxIF4HnbYYTlXXIqS+fPny3HFvh7WfuKbj8sm3wOyWmZi4MCBYppjgkC2U0XJJ0Up9MxSbX51xCCT7ZTygdY187777jO9uYEYYZ9nVk+UZVwhQRgLzzSCzgj8YZ9xD40rzOKZde+zzz6hRfG2a9dOzj+ZKzMVCWe2z7ll+zvuuMOXiVBRoqQohR748bVo0UJ+jETLZhIuImQxW5ARMYyAIezIvC925ClTpkgfNtw/Evv13//+EWr7Q/5m59bHWgLmB9xAEc26devKQiQBQ9nAfnjtY66NIDdrA8csxt0a5ptMouwHEtvhwcNCPuabdLAmQFprvle4ZXKhVJR8U7RCD9yO169fX36UZCTEnJIOUs0SMEQmx1w9ZViAJRMkAoIbH/z22+8J0Z+amDlPdiZOCq+VJcabPWduVj7cXOD4zCeffLK8vl69enK8sr3YsR9hfz7a5Mnl6xbJuUPiokw1qFxjFBjzzDPPlM/MXWC62TkXb5vThnTOYZn5FCVXilrogbw3NgUvP850HjAICLZfZnbkI88FgnowAzDztKYjZqVjx413Ro3+0Rn9w5jQGuNNnDwlrUil4uOPP5Zjc8UVV8hjWxg92yyMXHSi+HwctzVG6JlVE++A502uni4s7OJphHtkuokAF36bsx9bfpzXXZTio+iFHjDb2HKBl1xyidjkk2FR76KLLnI23XRTmYnnusjH3QR57vHIcOdMHz++VMTrhx/HhtYYr7RsUsbgHi/Ixc5xsSXwCBji8QsvvCCPgzKhdGI0ny8xrv18+M4jzn4SjmWC7wLBV4x3wQUXeAo4s357AcQcZ01xihIXVOgNmE9YaOTHSsQj0Z9EMiLoiLIt7oyNPpOd1g/kPMFt0ea8tzDjjUIISxIXEExDQXnggQfkc9tUvZ07d5bH2RQJ545i/ISySD7fpElT1hVEmTx5suwjtvIwwEbPYjRj4rGF3Z+ZPsnuSHxmYzNYE6AgiaLEDRV6FyQ7w67Lj9Y2xJ8ZPFGWPG7atKnZOjfwQ6egCSYG94UDG33YQkgbM3ZcVoFedsEan3B4//33sz4Oa9f+5pSUTAj9840aPcYpnzpt3RoERbzZRyJ5w4KoWMZkTYXvA4vTPLYNk14uZQsVJUpU6JPANY6MlZQcJPQdGzoLe4TAkxQtUy57v2BmIFrSpkK2TJ8xMxKhp/36a7CFSezbdrGaVACAmPGYu5Gg9m8ubuMiEfofnWnTZ6zbH0xh7CMLo2GBxxH1Bw444AAxt2GzZ4GadBBET+e6ZqMoUaJCnwbss5h0EP8wQundMPts1KiRCBILnpZZs+dEIvSMuWpVsBS5mJdYR7AFWIBIYezVzGiDevFg8hgztiSxL977mG1D6GfOmm3exZEcNBxXFkfDhgV57hhIaBeG66aiVAYq9HnEZsckq6Zl/vwFkQn9ihUrzLv4Ay8TBJ1oWJsFkvUKEr1hsw6aW33Fip+cH8eM89y/XBpCP2fueo8YUlVwXC+//HLToyjFjQp9HrEJst566y3Tgy/2EhEuL0HLpSH0S5YE8+smEpaALjxJbD4eAoAQfxaRM1XqSmbJ0qWe+5Zr47PNX7A+XxCunxzXq6++2vQoSnGjQp9HKEWIIL3yyiumB1vwisiEfoFLDP2AuYacQJhv7EIuuW+wfeNmijdKEBYuWhzZ3QoXSEsYNX0VpZBQoc8juHAiSB07djQ9jrPy558jE/o5c9JH/iYzYMAA2b/zzz/f9FQs0FqfcTxwgjBv3vxIPhvmIALQLNb3nxTBiqKo0OcVW6nI1iSFVatXe4pZrg2hnzEjWPI0GztA6UQ3NmiqU6dOpscfs2fPjUzoV65cvzBKMW/2j6pgiqKo0OcVG3xEDhULLoiE84/2ELRcGkJfXh7Mpk46XvaPHD9ubNrmYEFT/5MLTdhCz+caO67EWe1KHmaDvIJeiBSlUFGhzyOvvfaaCNItt9xiehxJwkUUKwLmJWzZNsYjmVgQbHUtIkDd2KCpIIudf/7vf87UqdMSQh/+5+LC6A4Gu/XWWz33W1GKFRX6PEK0KYJE9KmFNAXkpYlC6EvLJgYKciK3D/vnDuiCL7/8Unzpzz333HVpBzJB+gMyTEbxuUrGT9hgP2w0b9A1BEUpVFTo80jfvn1FMBs2bLhOqMhHP3HSlEgEcXzpxEDCTHZN9i85fwvlGPGl53n3Img6iASO6gJGIjg3l156qQi9n+philIMqNDnEXLc4L5IzhubN51o0/LyqZGYODAJkW/GD7hRUkmKoiPJqZuJEqZ6E6UQ/VbHYryoMnOWTawI5rKcddZZIvRap1VRKlChzyOjRo2SWqz4qbtTI0+bHtWi5XjfFY/I6cO+7b333hu9hgjbI488UvLykw7AD2vWrJX0B177lkvjc01JXBjdcKeB0PvdN0UpdFTo8whpBUiaRr5zd3oC8raEL/RksCzZwA0xHZQK5G6DylvJWS+x85PQC7MOGT/9gDdR2LN5GmOSCM7CvlG8nIAu0hUriqJCn1fIJUOKATJjUobOQt6WsE03NAksWuGvBGK/fv1kVnzxxRd7Ji8jZz/Ps50ffv55VWRCP3v2+mIgJBqjMDdrCGEnolOUqooKfR4hKRh5zEl5O3/+fNNLNauFkYgibcnSZeZd0tOlSxcRcrfrpxubvuHll182PekhoVlUQk8iOAsXT44pJqe5c+eaXkUpblTo8wyzT8wMs2evT7O7eMkST1HLtWEOIt+MH9q2bStCTpSpFx06dJDn77vvPtOTHhKqRSH0fCZ3nhvMYTvvvLOYb9x3SUp++PTTTyV5HwvkmWAbP9u5GTt2rAQcYgJVUqNCn2eOPfZYEcyysjLTQ+HwFZGl853nunNIBwU12K8ePXqYng0JWmmK7JJRCf2yxPGyUHSEwiBUl6JgtxIuJLLjvPtpdnuKtUQp9NaMqKRGj06e4YvNl9SdCZLEZlF4qCCKbnt2KljQpBA2+0Vudy9YhOV5Kk35Yc6cuZEJvbsAyMCBA2UR+ZxzzlnnsqqEB99TZuhLl65Pec33wC3QpK8+5phjzKPsBDwI7du3V6HPgB6dPNOkSRP5krqrTP3yy6+RCf2MGbMyRscinLh8knN+xIgRpndDZs2aJV43tWrV8hVtS56bSGz0ibZ69Xr3zw8//FCOZ+PGjQNXwFIyg6gmkyz0gMnGXgxU6POPHp08w2InX1J3XhaCmiSxWcjCyHjuItqpmDNnjhRFJ2AqlYsi7qBUmdppp518ldTjfcP/PBUuo+5auF27dpXjSX1fpXLwEno3VugRfltsB3OOu3BNKlu++zXJjX5wCz3/Y6+nMaZSgQp9nnnsscfkS/rEE0+Ynor0A1EU0Wa8SZOnyPjpoE4uAn744YdvFBVrwWOIoCmCqqhElYls0zqwVjGhdKJTNnGyU1q2YZtQOilxAdnQhdJm1tQUxZUHxzuT0GPKocAOwo3AI8RWqOlLZcvndTS2ofE/74dt3mKFnvEZm+0Yh/GUClTo88yrr74qX9LbbrvN9FQQVbqA0oQ4/v57+nw3pA7YZJNNnBNPPDFlbhxy15C6AY8hUjmkA9MOYh308yDy3w8d7rS5+17nyquaOlc3a75hu7q506JFS8lWibvnHXfcIYuwHE/2ncf0F3vj+DzzzDORrVn4FXo39CW/JrnPLvy+8847pmd9n9uEZIUegbe4Z/mKCn3e6d27t3whsSm7mThpcvhCn2gliTsFMmSmg2yV7BPZK1OBeLds2VK2S+WZY+FiMX5CWeDPg/nq60FDnH323VfeR1v2jbiCoMXh/cL4yaLtJpWoZxJ/Zu2M7RZ1L/H3EnUv8S9mVOjzjPVeoQ6rG4qEhC30tDGJWXJySoNkWC9gnzLVXM3ka2/h/bjAZDOjHzZilPNsx87Ogw8+tFG7P9Eef+JJCe4itz8lBP/2t7/J3QhrH2+++aY8p62LFEwnsVwU8B1IFnI3yQIOPOZ1bry2w7zjtufzGLNPptm77ePCoKjQ5x0Sb2H+OProozdYJMU7JgqhZ0zyzqTDCrh7JuWFNTthGkgHXkTjSrJfXOZugBTHyY3++fPXFzzn+OHuibcQuXqUyoHvQLJAu/EScB4ni7PXdgg6fvKIvX0ft30eVOgzo0KfZ8rLy8V7BTdFd273qPzOGfPnVem9ZKxJpmfPnqbHG2aJbNeoUSPT4w1eOXjHhF0eEXfRWbPWxwUsW7bMOeSQQ2QhecqUKaZXiRorwKnwEnAeJ4tzqu0yibUKfWZU6PMMOW4OOuggp0aNGhuIE5GkUSQ2Q+jdkaRe2B/hkCFDTI83gwcPdrbYYguZRadLfxxlpO+cuesjfTmWXDTJdaNRsZUDtnK+K8y4vezh9PFcsrnFes/YPrtd8jh2bHsRwHSDiLsF3EbGuvtIi0CfulhWoEKfZxAkPEUI23cHJ5HvBiHzErhcGkLvzg2TDIuszIr5kWTK/ojZaZdddpE0ywsXrjehJBNVnhvGXLBgkXmXioIo2Odr167tK4hLyQ07IXA3RNhN8vOIsZ8+C8JuLwrJjdcl7wPv79VX7KjQ5xk8Ui688EKJMnXPPsj2GJXQz3Nle0yGAiiYPkjzm2lWvGDBAjE57bbbbmKCSsXChYsiuTuhcRGxDB8+XH7Yp556qulRqjLM7JmZJ0M/4q0C7h8V+hhw7bXXikB169bN9EScv31O6vS9mI9YzDz00EMzVqPCl55qTiwm//jjj6Z3Y+bNmx/JRQtzEGYhi01/cOWVV5oepSrDzDyVmDMpcrtYKulRoY8BXm6KRJ5GYddG6KdPT13nddCgQWL+qFevngh5Jkgexr6nC5qaNXtOJEKPqygXREvHjh1lX/ymTlbiDSYbbPtEvFr7O38ReK+ZvpIaFfoYwBcZgWrdurXpofTemsjSICTXWHXTq1cv2ZfmzZv7snPbdMZvv/226dkQxqDUX9hCT56bseNKxHXTQhQo+8LxVKo+1nTDYiznlcYsX2fywVGhjwF9+/aVWTRl++wsmiCjbKJJMzXGI+o2FU8//bT8oB588EHTkx5yyrC9O1ePG3zbowj+YjwiZ91BQBw/9oXIXkVR1qNCHwNGjx4tycHq1q0ri6GA4JPIKwqBLC2bmBBg78RmBD8hlgRD+YHoU7a//vrrTc+G/PHf/2ad0CxdYzyibd0J2o477jjZlzFjxpgeRVFAhT4GLFq0SMrf4Utvs0X+8cd/nUmTyyMRSBKMpbK/X3755SKW7vz46fjqq69k+/r165ueDcGrKJuEZpka43HHY81LBJtRlhGb7tSpqU1TilKMqNDHAMwbuClivpk5s2KhFAEjh3v4tu3ETHh8qWcmQ/oIfiIIimAoP5CvHqEnZbEXmFYkz43HvuTS+BxuExSplblY4i2UzqdfUYoRFfqYYIM83AI7bfqMSISeRV53VSYLAkkOeoKgJkyYYHrTQwFuzE7cjXjl0GGtISrvIS6EFltCEG+hTLl8FKXYUKGPCdi4Efo33njD9DjOzFmzwxf6RCPvzMqVG+e7wYee4CdSMpBOwA8EVbE9AVbuikGWXxKiiyh77UsujTFJ/Gbp3r27HD/y9CiKsiEq9DHB+oDffffdpsdx5s6dF4n/eXKgkYVF4c0220wWhf340IPb3GN9nd1EGfhF4jfL448/Lsfv4YcfNj2KolhU6GNCv379RKhwEbQsWLgoMpF0pw6w2IXV8847z/RkhvUFIlF53fvvv29618MFJYrPQEqFBQsqbPGsZ9iMm+7oYkVRKlChjwnk2GY2TTSgnU0jxl4il2vjLoH8M8lY80erVq1Mjz/uueceeV2nTp1Mz3pIoBaN0P+YGLviYkWqhpNOOsnZcsstM2bcVJRiRIU+JuBtQ3rdffbZZ53nzfIVP0WW3nfuvI1t8O3atRPBpmB5EJ5//nl53V133WV61jN//oLIhJ7jA7ik7rHHHuJ143dtQVGKCRX6mEBxDgpab7XVVutmpdi3oxJ6t33b4pVczQ/vvfeevM4rmVhUBVT4DDbPjXXxxLVSUZSNUaGPCdiZmzZtKoJl88bgJoiHjJfQ5dJkRj93nryHGz8JyrxgexZjcRFNdm0kc2UUQs8F0LqI9unTR/b7kksukceKomyICn2MwGSCYD300EPymPD+ceOyr7WaqiH0ixYtlvdwgw897x80srSkpMSpXr26FObGr97NkqXLQt9/xiMIywZ9JR83RVE2RIU+RlCDlQIkl156qaQOgEmTw80Tk8qPnrTIBErhD+8u5eYH7OIHHnigBE0l+9KzUOq1H7k0jsfkKeXr8tw0bNhQhN5v2gZFKTZU6GPExIkTnWrVqjkHH3yw2OwBF0Jm4F6Cl01DJMk9404GBlSI4r0pI2jf2y94CR199NHiNTRu3DjTWwE5e8JOaoZrpTU9MavnToKoWO4sFEXZGBX6GMEsntzbVGyaMWOG9CFkJePDy0vPOBQeT+abb74RoT7zzDMlbUFQSD3ArNorR87CRYtDFXrSE5OvH8rKypxdd91VEprNm7fxuoOiKCr0saNBgwYimOSot+AKGcasvmI2X+YZ9WoLjjRr1mxdRsgg2IClnj17mp71cAErLZsUymdgDLfHEMeJCyPZM/1G8ypKsaFCHzNsKP/9999veioWZUlZnKtQ4qmyIkXB76AFR5KxBUjYfy9YE6D0Xy5ZLLlQcRzcgk75Rd7XnTpCUZQNUaGPGf379xfhwtXRDSacbGfF1mxC3vtU2IIj2Zbhe+utt+T11113nenZGIn0ReyzMOPwubkb+dV42gAXwEaNGsn7ckeiKIo3KvQxY9KkSc5OO+0kNufkKE9s51OmTBWh9CuWCCSuiEuXLjOjbAymmssuu0wE8z//+Y/pDQZBXrz+jDPOMD3eLFu2XPLhBxH70YnPMGVK+Tq7vIXMmaxpbLfddnLcFEXxRoU+ZiBexx9/vORt8coGySx20cJF68QSDxQr/LYh7vzFVDN9+owNCmh7gZcNuWL+8pe/ON99953pDcasWbNkMXf//fdf5xqaCoKqKBjO/rn3191sH5+TxWNKEiaDuOOOWrt27Y28iBRFWY8KfQz597//LbNjd276ZBBTZukUJ8F9EZdJWtnESc7kxKyfBVx82P0srM6ZM0cqXJEvhpz02UApP2bXlPKbPn266U0N+0Wu+nmJu5Yp5dNkvzHNlCY+A5WjpiXGIIfN77+nvmiw8MtxatKkielRFMULFfoY0rlzZxEw7OZ+IFUwJftomWbTXuCiuO222zqHHXaY3FFkA2sIuGYyq6faU1DY77VrKz6D39n5HXfcIcfJK2umoijrUaGPIeSOwWXw1FNPzcqnPShDhw4VwcR8kwu2Stbrr79ueqKF9QDeL2huHkUpNlToYwjeMTvssIMEAmU7ww4CqRcQzFxNINZF0+0aGhWkacA2z0IsEcWKoqRGhT6mHHHEESKamFWi5plnnpH3euCBB0xPdlBhyl4wMCdFyQ8//CAXwzp16myUSE1RlA1RoY8pNlFXtu6OQbjpppvkvXI1ueAlhOcOefWD5ssJyieffCIeNxdeeKF63ChKBlToYwoRqojvk08+aXqigxqxvFc2i6huyM+z5557Ovvuu6948kTJSy+9JPvsd8FaUYoZFfqY0qNHDxEyXC2jxuahJ4NlLuAxg8mJTJKlpaWmNxooW8g+46GkKEp6VOhjyqBBg0TIcFmMEkwsu+22m/i/47eeK9lWqQoCphpMW5huevfubXoVRUmFCn1MGTNmjNi7jznmGAl8igrrQ89MfOXKlaY3e6y9/7XXXjM94UNk7T/+8Q+prztq1CjTqyhKKlToYwrRpXvvvbdEm86ePdv0hs+AAQPEZ5+ZOKaXXHnuuedE6Nu0aWN6wgeX03322Ue8bjQHvaJkRoU+puBLf+SRRzo777yzM378eNMbPjbr5DXXXJNVHvpk+vXrJ+NFWagbExN3O5Qu1Bz0ipIZFfqYgrnm5JNPluRm2SYa84MtrM3fMMAUxHiU94sK6tLyHiwiK4qSGRX6mMLs+vzzzxdBw7wSFTZtQdeuXU1PbpBaGZMKbpZRRfWOHDlS9vmUU04xPYqipEOFPsZcccUVImh9+vSRnDcLFiwwz4QDicQIONpkk03E5BIGK1askNn89ttvH6rJic++atUq+Z8LH8eFfVcUJTMq9DGmRYsWImgff/yxhPwfdNBBzgsvvBBaegFSC9etW1fyxYwYMcL05gYLutyJsMD7+eefm97s4c6GdM18dntnY3PzXH311fJYUZT0qNDHmJtvvlkE7e2335YFyIMPPlge49kSBnjzEMWKd8/MmTNNb+7ceOONsp9dunQxPdlDWgbuOPCysfvI8WD8dGULFUVZjwp9jLH51q1gfvHFF2L/3nrrrUNJdsYYeK+wqBmmr3779u1lv9u2bWt6sgNh5/Nus802Yr6yIP6M37p1a9OjKEo6VOhjzN133y2C9uKLL5qeCvs03jhhRIQOGzZMxme8MLHpG1q2bGl6suPLL7+UBGkkMHNDAXPGv/POO02PoijpUKGPMTaxWceOHU1PBaQtoKJTrlhb95VXXml6wgGBJt/N2WefndN+8lqvaF0VekUJhgp9jEkl9GHx7LPPyvj33Xef6QmHkpISZ6eddpKArzDy5ySjQq8owVChjzFhCT3pFDADHXvssRIJa8HGzfivvvqq6QkHCoHst99+UiELv/oPP/zQ+fvf/y4phbMtPu5GhV5RgqFCH2OsjR6Xymx57733xLOGcWhul8SLL75Y+sJwg3SD+ye+9LhYTp061bnlllvWvT+BVN26dTNbZgcXJsa6/fbbTY+iKOlQoY8x5KJH0Hr16mV6/EMq3w4dOkiGRyuypPV1XzSY4dMfRS6devXqydhEsbL/uEja/dhiiy2cdu3aScBWNtiShU2bNjU9iqKkQ4U+pjArbtCggQjaZ599Znr9g6AjqFZcaQQdLVy4UJ4nsAn/eS4EUWSAtBepd955RxZUsde792WzzTZznnrqKbN1MMj9wxinn3666VEUJR0q9DEFcfznP/8pPuRBo1b79+8v/vFuYcULpmfPnmYLx5k1a5ZTvXp1SYO8dOlS0xsejzzyiLwvPvWAHzwJ2tz7xIWIqN+gsO/cndSqVSuUjJuKUuio0McUolYPPPBAmXVj5/YLM/Y6depsIKg0FkLdphIuHgReHX/88c7q1atNb3hQeIT3xT4P3KHcf//9G+1X7dq1A9eXJZ/OLrvsIp49pHFQFCU9KvQxZdy4cU61atVEtINUfsIunyymLMCSFM1N3759ZVZ86aWXZm0rTwfmJt6b8S2Yi1q1arXR/j366KOBZuZE8bK+wF3L2LFjTa+iKKlQoY8pQ4YMERHEDu1XBBHAE044YZ2AIuTky/GasdsZN6X/ooBSiIzP/rihDCDVp/DIsfuJh47NTOkHLkwXXXSRfL6wsm4qSiGjQh9TcItEBINkaEQsMcVgC6cGbPfu3cX7xgtbcATvlyjAdx9PGxKxJV+oeMznO/roo2UxGKEPWq/WxgC8/PLLpkdRlFSo0MeUp59+WoSMoKkgYPIhN8yyZctMjzfWtz2MDJNeYHfHhk7WyVQijq39008/lRTMQbFRvdj9FUVJjwp9TMGkgpBhYgkbZtSNGzeW8YlajQKiY1lMJjo2zBTIFjyI2P/mzZubHkVRUqFCH1Moro2QMeMNG5KFkXAMl8uvv/7a9IYLs3VMM6QZjiIgi2hejs8FF1wQyWKyohQSKvQxhdTBCNnw4cNNT3jgkojXCl49o0aNMr3hwnoBC7HY4IcOHWp6w+Pbb78VP/x//etfgRZyFaUYUaGPKfi942NOUrCwwdWS9AEs3EYRLAUsApOLhojYKEw3c+fOdY477jipMvX777+bXkVRvFChjyn4nEc5U0XsowiUchP1Z2D/k+MDFEXZGBV6RVGUAkeFXlEUpcBRoVcURSlwVOgVRVEKHBV6RVGUAkeFXlEUpcBRoVcURSlwVOgVRVEKHBV6RVGUAkeFXlEUpcBRoVcURSlwVOgVRVEKHBV6RVGUAkeFXlEUpcBRoVcURSlwVOhjxFlnnSVVpTK1Aw44wLzCkcIb9PHaqgSfIflzJTf351QUJXtU6GOIW+ySQdjdAmgvDlVN6GHatGnrPqf7M73zzjvr+mlspyhK9qjQxxC3yHmB2BcCqYQe7J0KrX379qZXUZRsUKGPIVbgaBaKYTPTdeM29SQLZTozEGOxvX3Mtm7RpbnF1d1vLzL2MWNZeI1720yo0CtK5aBCH0OswNEsCGGy0IMVbLdQ2j4rylY0k8XUvoc1+yDats8trm5BZizGsWPafUp+bPchHamE3m26qYomKUWJGyr0McSKXHLzI/Rusbbbu4XTPQO3fUGEnsZjuy1/3a+z2DsKr322JI+b3HheUZTcUaGPIW6xsyDkcRB6rxl2ssnG3exdhRfuce3+W9xjuPdZUZTgqNDHELfIWRA7P0IPts+KrDWrpBLTIELvJdx2fFqQWXg6oXdfnJKfUxQlGCr0McQKHC0TVtSTxdAtvjQvgbbPhSn0QWbf6YTevS80RVGyR39BMSSIwHkJPSLpZWJJxr5HrkLvnn17PZ8KndErSuWgQh9DrMDRMuEl9O7XJzfE1YLA02eF3j6mBRF6sPtBs7N6xNo9TjKphD55Nm/HUxQlO1ToY4RbaN3NCnEyydvb7dx9Xs3iFloaoux+bNcE3H20VPvjFntautl98rZeLdX7KIoSDBX6AiRZwJObe1avKErho0JfYFiRt7NxN9burUKvKMWFCn2BYe3bXmYTTCFBFksVRSkMVOgLkOTFTNu8ZvmKohQ+KvSKoigFjgq9oihKgaNCryiKUuCo0CuKohQ4KvSKoigFjgq9oihKgaNCryiKUuCo0CuKohQ4KvSKoigFjgq9oihKgaNCryiKUuCo0CuKohQ4KvSKoigFjeP8fweUmDlUBYBeAAAAAElFTkSuQmCC" alt="" width="378" height="364" vspace="0" hspace="0" border="0" style="width:378px;height:364px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p></td></tr></tbody></table><p>The recommended subcutaneous injection sites include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The thigh</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abdomen, except for a two‑inch area right around the navel</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Outer area of upper arm</p><p>Clean the injection sites with alcohol wipes. Let the skin dry.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Choose a different site each time you give an injection. If you want to use the same injection site, make sure it is not the same spot on the injection site you used for a previous injection.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not inject into areas where the skin is tender, bruised, red, or hard. Avoid injecting into areas with scars or stretch marks.</p><p>&nbsp;</p><p>Choose the first syringe. Pull the gray needle cap straight off and away from your body when you are ready to inject. See Figure C.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Figure C</strong><img alt="" width="264" height="313" src="data:image/png;base64,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" /></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not<strong> </strong>put the gray needle cap back onto the syringe.<strong> </strong></p><p><strong>Step 3: Inject EVENITY</strong></p><p>Insert needle and inject all the liquid subcutaneously. Do not administer into muscle or blood vessel. See Figure D.</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<img src="data:image/png;base64,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" alt="" width="459" height="316" vspace="0" hspace="0" border="0" style="width:459px;height:316px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>When done, gently lift the syringe off of the skin.</p><p><strong>&nbsp;</strong></p><p><strong>Step 4: Syringe and Needle Cap Disposal</strong></p><p><strong><u>&nbsp;</u></strong></p><p>Immediately dispose of the syringe and needle cap in the nearest sharps container.</p><p>&nbsp;</p><p><strong>Important: Repeat all steps with the second syringe to inject the full dose.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                EVENITY is contraindicated in patients with:
•	Hypocalcemia. Pre-existing hypocalcemia must be corrected prior to initiating therapy with EVENITY [see Special Warnings and Precautions for use (4.4), Undesirable effects (4.8) and Fertility, pregnancy & Lactation (4.6)].
•	A history of systemic hypersensitivity to romosozumab or to any component of the product formulation. Reactions have included angioedema, erythema multiforme, and urticaria [see Special Warnings and Precautions for use (4.4) & Undesirable effects (4.8)

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Major Adverse Cardiac Events (MACE)</p><p>In a randomized controlled trial in postmenopausal women, there was a higher rate of major adverse cardiac events (MACE), a composite endpoint of cardiovascular death, nonfatal myocardial infarction and nonfatal stroke, in patients treated with EVENITY compared to those treated with alendronate <em>[see Undesirable effects (4.8)]</em>.</p><p>&nbsp;</p><p>EVENITY should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year. Consider whether the benefits outweigh the risks in patients with other cardiovascular risk factors. Monitor for signs and symptoms of myocardial infarction and stroke and instruct patients to seek prompt medical attention if symptoms occur. If a patient experiences a myocardial infarction or stroke during therapy, EVENITY should be discontinued.</p><p>Hypersensitivity Reactions</p><p>Hypersensitivity reactions, including angioedema, erythema multiforme, dermatitis, rash, and urticaria have occurred in EVENITY-treated patients. If an anaphylactic or other clinically significant allergic reaction occurs, initiate appropriate therapy and discontinue further use of EVENITY <em>[see Contraindications (4.3) and Undesirable effects (4.8)].</em></p><p>Hypocalcemia</p><p>Hypocalcemia has occurred in patients receiving EVENITY. Correct hypocalcemia prior to initiating EVENITY <em>[see Contraindications (4.3), Special Warnings and Precautions for use (4.4), Undesirable effects (4.8) and Fertility, pregnancy &amp; Lactation (4.6)].</em></p><p>Monitor patients for signs and symptoms of hypocalcemia. Patients should be adequately supplemented with calcium and vitamin D while on EVENITY <em>[see </em><em>Posology and method of administration</em><strong><em> </em></strong><em>(</em><em>4</em><em>.2) and Clinical Studies (</em><em>5.5</em><em>)]</em>.</p><p>&nbsp;</p><p>Patients with severe renal impairment (estimated glomerular filtration rate [eGFR] 15&nbsp;to 29&nbsp;mL/min/1.73&nbsp;m<sup>2</sup>) or receiving dialysis are at greater risk of developing hypocalcemia. Monitor serum calcium and adequately supplement patients who have severe renal impairment or are receiving dialysis with calcium and vitamin D. Instruct patients with severe renal impairment, including those receiving dialysis, about the symptoms of hypocalcemia and the importance of maintaining calcium levels with adequate calcium and vitamin D supplementation.</p><p>&nbsp;</p><p>Osteonecrosis of the Jaw</p><p>Osteonecrosis of the jaw (ONJ), which can occur spontaneously, is generally associated with tooth extraction and/or local infection with delayed healing, and has been reported in patients receiving EVENITY. A routine oral examination should be performed by the prescriber prior to initiation of EVENITY treatment. Concomitant administration of drugs associated with ONJ (chemotherapy, bisphosphonates, denosumab, angiogenesis inhibitors, and corticosteroids) may increase the risk of developing ONJ. Other risk factors for ONJ include cancer, radiotherapy, poor oral hygiene, pre-existing dental disease or infection, anemia, and coagulopathy<em> </em><em>[see Undesirable effects (4.8)].</em></p><p>For patients requiring invasive dental procedures, clinical judgment of the treating physician and/or oral surgeon should guide the management plan of each patient based on benefit‑risk assessment. Patients who are suspected of having or who develop ONJ while on EVENITY should receive care by a dentist or an oral surgeon. In these patients, dental surgery to treat ONJ may exacerbate the condition. Discontinuation of EVENITY should be considered based on benefit‑risk assessment.</p><p>&nbsp;</p><p>Atypical Subtrochanteric and Diaphyseal Femoral Fractures</p><p>Atypical low‑energy or low trauma fractures of the femoral shaft have been reported in patients receiving EVENITY <em>[see Undesirable effects (4.8)]. </em>These fractures can occur anywhere in the femoral shaft from just below the lesser trochanter to above the supracondylar flare and are transverse or short oblique in orientation without evidence of comminution. Causality has not been established as these fractures also occur in osteoporotic patients who have not been treated.</p><p>Atypical femoral fractures most commonly occur with minimal or no trauma to the affected area. They may be bilateral and many patients report prodromal pain in the affected area, usually presenting as dull, aching thigh pain, weeks to months before a complete fracture occurs.</p><p>During EVENITY treatment, patients should be advised to report new or unusual thigh, hip, or groin pain. Any patient who presents with thigh or groin pain should be suspected of having an atypical fracture and should be evaluated to rule out an incomplete femur fracture. Patient presenting with an atypical femur fracture should also be assessed for symptoms and signs of fracture in the contralateral limb. Interruption of EVENITY therapy should be considered based on benefit‑risk assessment <em>[Clinical Studies (5.5)].</em></p><p><strong>Sodium content </strong></p><p>This medicinal product contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially sodium-free.</p><p><em>&nbsp;</em></p><p><strong><em>Special populations:</em></strong></p><p>Pediatric Use</p><p>Safety and effectiveness of EVENITY have not been established in pediatric patients.</p><p>Geriatric Use</p><p>Of the 6544 postmenopausal women with osteoporosis in the clinical studies of EVENITY, 5234 (80%) were age 65 years and over and 2390 (37%) were age 75 years and over. No overall differences in safety or efficacy were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in response between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.</p><p>Renal Impairment</p><p>No dose adjustment is required in patients with renal impairment.</p><p>&nbsp;</p><p>Patients with severe renal impairment (estimated glomerular filtration rate [eGFR] 15&nbsp;to 29&nbsp;mL/min/1.73&nbsp;m<sup>2</sup> by MDRD equation) or receiving dialysis are at greater risk of developing hypocalcemia <em>[see Contraindications (4), Warnings and Precautions (5.3) and Adverse Reactions (6.1)]</em>. Monitor calcium concentrations and adequately supplement calcium and vitamin D in patients who have severe renal impairment or are receiving dialysis.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>.No drug interaction studies have been performed with romosozumab. No pharmacokinetic drug interactions are expected with romosozumab.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy</p><p><u>Risk Summary</u></p><p><u>&nbsp;</u></p><p>EVENITY is not indicated for use in women of reproductive potential. In animal reproduction studies, weekly administration of romosozumab to pregnant rats during the period of organogenesis at exposures greater than 31 times the clinical exposure produced skeletal abnormalities in the offspring. Administration of romosozumab to rats prior to mating and through to the end of lactation produced minimal to slight decreases in femoral bone mineral density and/or cortical circumferences in the offspring at 1.4 to 54 times the expected exposure in humans <em>[see Data]</em>.</p><p>&nbsp;</p><p><u>Data</u></p><p><em>Animal Data</em></p><p>Reproductive and developmental effects of romosozumab were assessed in the rat in a preliminary and definitive embryo‑fetal development study, a combined fertility and embryo‑development study, and a pre‑ and postnatal development study.</p><p>&nbsp;</p><p>Skeletal malformations including syndactyly and polydactyly occurred in 1 out of 75&nbsp;litters across all rat reproductive toxicity studies, in the litter of a dam given weekly subcutaneous romosozumab doses of 300&nbsp;mg/kg (equivalent to at least 31 times the clinical exposure observed in humans following a monthly subcutaneous dose of 210&nbsp;mg, based on area under the concentration‑time curve [AUC] comparison).</p><p>&nbsp;</p><p>In the offspring of female rats given weekly romosozumab doses from 6 weeks before cohabitation through mating and lactation, femoral periosteal and endocortical circumferences were slightly decreased at 10, 60, and 300 mg/kg (equivalent to 1.4, 18, and 54 times the clinical exposure following a monthly subcutaneous dose of 210&nbsp;mg, based on AUC comparison). Cortical thickness was increased at 300 mg/kg (equivalent to 54 times expected clinical exposure). Femoral metaphyseal bone mineral density was slightly decreased at 60 and 300 mg/kg (equivalent to 18 and 54 times expected clinical exposure).</p><p>&nbsp;</p><p>4.6.2&nbsp;&nbsp;&nbsp; Lactation</p><p><u>Risk Summary</u></p><p>EVENITY is not indicated for use in women of reproductive potential. In animal studies where pregnant rats were given weekly doses of romosozumab from 6 weeks before cohabitation through mating and lactation at 10, 60, or 300&nbsp;mg/kg (equivalent to 1.4, 18 or 54 times the clinical exposure following a monthly subcutaneous dose of 210&nbsp;mg, based on AUC comparison), romosozumab was dose‑dependently present in the serum of offspring on postnatal day 21 at 0.01 to 2.4 times maternal exposure due to gestational and/or lactational exposure.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>.Romosozumab has no or negligible influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The following adverse reactions are discussed in greater detail in other sections of the label:</p><ul><li>Major adverse cardiac events <em>[see Special Warnings and Precautions for use (4.4)]</em></li><li>Hypersensitivity <em>[see Contraindications (4.3), Special Warnings and Precautions for use (4.4)]</em></li><li>Hypocalcemia <em>[see Contraindications (4.3), Special Warnings and Precautions for use (4.4)]</em></li><li>Osteonecrosis of the Jaw<em> [see Special Warnings and Precautions for use (4.4)]</em></li><li>Atypical Subtrochanteric and Diaphyseal Femoral Fractures <em>[see Special Warnings and Precautions for use (4.4)]</em></li></ul><p>&nbsp;</p><p>4.8.1&nbsp;&nbsp;&nbsp; Clinical Trials Experience</p><p>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p><p>The safety of EVENITY for the treatment of postmenopausal osteoporosis was evaluated in a multicenter, randomized, double‑blind, placebo‑controlled study (Study 1, NCT01575834) of 7180&nbsp;postmenopausal women aged 55 to 90&nbsp;years (mean age of 71&nbsp;years). A total of 3581 and 3576&nbsp;women received at least one dose of EVENITY and placebo, respectively, administered once every month during the 12‑month double‑blind study period. Women received at least 500&nbsp;mg calcium and 600&nbsp;international units of vitamin D supplementation daily and 77% received a loading dose of 50,000 to 60,000 international units of vitamin D within one week of randomization (if serum 25-hydroxyvitamin D concentrations were 40&nbsp;ng/mL or less).</p><p>The safety of EVENITY for the treatment of postmenopausal osteoporosis in patients at high risk of fracture was evaluated in a multicenter, randomized, double-blind, alendronate-controlled study (Study 2, NCT01631214) of 4093 postmenopausal women aged 55 to 90 years (mean age of 74 years). A total of 2040 and 2014 women received at least one dose of EVENITY and alendronate, respectively, during the 12-month double-blind study period. Women received at least 500 mg calcium and 600 international units vitamin D supplementation daily and 74% received a loading dose of 50,000 to 60,000 international units of vitamin D within one week of randomization (if serum 25-hydroxyvitamin D concentrations were 40&nbsp;ng/mL or less).</p><p>In Study 1, during the 12-month double-blind treatment period, the incidence of all‑cause mortality was 0.7% (24/3576) in the placebo group and 0.8% (29/3581) in the EVENITY group. The incidence of nonfatal serious adverse events was 8.3% in the placebo group and 9.1% in the EVENITY group. The percentage of patients who withdrew from the study due to adverse events was 1.1% in the placebo group and 1.1% in the EVENITY group. The most common adverse reactions reported with EVENITY (greater than or equal to&nbsp;5% and at a higher incidence than placebo) were arthralgia and headache. The most common adverse reaction leading to discontinuation of EVENITY was arthralgia (6 subjects [0.2%] in the placebo group and 5 subjects [0.1%] in the EVENITY group).</p><p>&nbsp;</p><p>In Study 2, during the 12-month double-blind treatment period, the incidence of all-cause mortality was 1.1% (22/2014) in the alendronate group and 1.5% (30/2040) in the EVENITY group. The incidence of nonfatal serious adverse events was 13.3% in the alendronate group and 11.9% in the EVENITY group. The percentage of patients who withdrew from the study due to adverse events was 1.2% in the alendronate group and 1.2% in the EVENITY group. The most common adverse reactions reported with EVENITY (greater than or equal to&nbsp;5%) were arthralgia and headache.</p><p>&nbsp;</p><p><strong>Table 1 outlines the most common adverse reactions occurring in greater than or equal to 2% of EVENITY treated women in at least one study.</strong></p><p>Table <!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt;mso-ascii-font-family:"Times New Roman";
mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi;mso-no-proof:yes'><span style='mso-element:field-begin'></span><span
style='mso-spacerun:yes'> </span>SEQ Table \* ARABIC <span style='mso-element:
field-separator'></span></span><![endif]-->1<!--[if supportFields]><span style='mso-bidi-font-size:
11.0pt;mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
mso-no-proof:yes'><span style='mso-element:field-end'></span></span><![endif]--> Adverse Reactions Occurring in &ge; 2% of EVENITY‑Treated Women in at Least One Study (Studies 1 and 2)</p><table border="0" cellspacing="0" cellpadding="0" align="left" style="width:642px"><tbody><tr><td style="vertical-align:bottom"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:bottom"><p><strong>Study 1</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Study 2</strong></p></td></tr><tr><td style="vertical-align:bottom"><p><strong>Preferred Term</strong></p></td><td style="vertical-align:bottom"><p><strong>Placebo </strong></p><p><strong>&nbsp;(N = 3576) </strong></p><p><strong>&nbsp;n (%)</strong></p></td><td style="vertical-align:bottom"><p><strong>EVENITY</strong></p><p><strong>&nbsp;(N = 3581) </strong></p><p><strong>&nbsp;n (%)</strong></p></td><td style="vertical-align:top"><p><strong>Alendronate</strong></p><p><strong>(N = 2014)</strong></p><p><strong>n (%)</strong></p></td><td style="vertical-align:top"><p><strong>EVENITY</strong></p><p><strong>(N = 2040)</strong></p><p><strong>n (%)</strong></p></td></tr><tr><td><p>Arthralgia</p></td><td><p>434 (12.1)</p></td><td><p>468 (13.1)</p></td><td><p>194 (9.6)</p></td><td><p>166 (8.1)</p></td></tr><tr><td><p>Headache</p></td><td><p>208 (5.8)</p></td><td><p>235 (6.6)</p></td><td><p>110 (5.5)</p></td><td><p>106 (5.2)</p></td></tr><tr><td><p>Muscle spasms</p></td><td><p>140 (3.9)</p></td><td><p>163 (4.6)</p></td><td><p>81 (4.0)</p></td><td><p>70 (3.4)</p></td></tr><tr><td><p>Edema peripheral</p></td><td><p>67 (1.9)</p></td><td><p>86 (2.4)</p></td><td><p>38 (1.9)</p></td><td><p>34 (1.7)</p></td></tr><tr><td><p>Asthenia</p></td><td><p>79 (2.2)</p></td><td><p>84 (2.3)</p></td><td><p>53 (2.6)</p></td><td><p>50 (2.5)</p></td></tr><tr><td><p>Neck pain</p></td><td><p>54 (1.5)</p></td><td><p>80 (2.2)</p></td><td><p>42 (2.1)</p></td><td><p>34 (1.7)</p></td></tr><tr><td><p>Insomnia</p></td><td><p>68 (1.9)</p></td><td><p>72 (2.0)</p></td><td><p>36 (1.8)</p></td><td><p>34 (1.7)</p></td></tr><tr><td><p>Paresthesia</p></td><td><p>62 (1.7)</p></td><td><p>72 (2.0)</p></td><td><p>34 (1.7)</p></td><td><p>29 (1.4)</p></td></tr></tbody></table><p>&nbsp;</p><p>The adverse reactions described below are from the 12‑month treatment periods of Study 1 (placebo-controlled) and Study 2 (alendronate-controlled).</p><p><em>Major Adverse Cardiac Events (MACE)</em></p><p>During the 12‑month double‑blind treatment period of the placebo‑controlled trial (Study 1), myocardial infarction occurred in 9 (0.3%) women in the EVENITY group and 8 (0.2%) women in the placebo group; stroke occurred in 8&nbsp;(0.2%) women in the EVENITY group and 10 (0.3%) women in the placebo group<em>.</em> These events occurred in patients with and without a history of myocardial infarction or stroke. Cardiovascular death occurred in 17 (0.5%) women in the EVENITY group and 15 (0.4%) women in the placebo group. The number of women with positively adjudicated MACE was 30 (0.8%) in the EVENITY group and 29 (0.8%) in the placebo group, yielding a hazard ratio of 1.03 (95% confidence interval [0.62, 1.72]) for EVENITY compared to placebo.</p><p>During the 12‑month double‑blind treatment period of the active‑controlled trial (Study 2), myocardial infarction occurred in 16 (0.8%) women in the EVENITY group and 5 (0.2%) women in the alendronate group; stroke occurred in 13&nbsp;(0.6%) women in the EVENITY group and 7 (0.3%) women in the alendronate group. These events occurred in patients with and without a history of myocardial infarction or stroke. Cardiovascular death occurred in 17 (0.8%) women in the EVENITY group and 12 (0.6%) women in the alendronate group. The number of women with positively adjudicated MACE was 41 (2.0%) in the EVENITY group and 22 (1.1%) in the alendronate group, yielding a hazard ratio of 1.87 (95% confidence interval [1.11, 3.14]) for EVENITY compared to alendronate <em>[see Special Warnings and Precautions for use (4.4)].</em></p><p><em>Hypersensitivity Reactions</em></p><p>Across both trials, hypersensitivity reactions were reported in 364 (6.5%) women in the EVENITY group and 365 (6.5%)&nbsp;women in the control group. Reported reactions included angioedema (3 [&lt;&nbsp;0.1%] women in the EVENITY group vs. 3 [&lt;&nbsp;0.1%] women in the control group), erythema multiforme (1 [&lt;&nbsp;0.1%] woman in the EVENITY group vs. no woman in the control group), dermatitis (32 [0.6%] women in the EVENITY group vs. 42 [0.8%] women in the control group), rash (60 [1.1%] women in the EVENITY group vs. 53 [0.9%] women in the control group), and urticaria (23 [0.4%] women in the EVENITY group vs. 27 [0.5%] women in the control group). Although angioedema, dermatitis and urticaria were not reported at a higher incidence with EVENITY than control, there were cases of angioedema, dermatitis and urticaria that were determined to be related to EVENITY use <em>[see Contraindications (4.3) and Special Warnings and Precautions for use (4.4)]</em>.</p><p><em>Hypocalcemia</em></p><p>Across both trials, adverse events of hypocalcemia occurred in 2 EVENITY‑treated women and in 1 woman in the control group. Decreases in albumin‑adjusted serum calcium to below the lower limit of the reference range (8.3&nbsp;mg/dL) were reported in 14 (0.2%) women in the EVENITY group and 10 (0.2%) women in the control group. No patient receiving EVENITY developed serum calcium less than&nbsp;7.5&nbsp;mg/dL. The nadir in albumin‑adjusted serum calcium occurred by month&nbsp;1 after EVENITY dosing in patients with normal renal function <em>[see Contraindications (4.3) and Special Warnings and Precautions for use (4.4)]</em>.</p><p><em>Injection Site Reactions </em></p><p>Across both trials, injection site reactions occurred in 278 (4.9%) women in the EVENITY group and 157 (2.8%) women in the control group. The most common injection site reactions were pain (94 [1.7%] women in the EVENITY group; 70 [1.3%] women in the control group) and erythema (80 [1.4%] women in the EVENITY group and 14 [0.3%] women in the control group). Injection site reactions resulted in discontinuation of treatment in 7 (0.1%) EVENITY‑treated patients and 3 (&lt; 0.1%) patients in the control group.</p><p>&nbsp;</p><p><em>Osteonecrosis of the Jaw</em></p><p>Across both trials, osteonecrosis of the jaw occurred in one patient during treatment with EVENITY. <em>[see </em><em>Special Warnings and Precautions for use (4.4)]</em>.</p><p>&nbsp;</p><p><em>Atypical Subtrochanteric and Diaphyseal Fractures</em></p><p>Across both trials, atypical femoral fracture occurred in one patient during treatment with EVENITY <em>[see </em><em>Special Warnings and Precautions for use (4.4)]</em>.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>To report any side effects:</p><p>Saudi Arabia:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance Centre (NPC):</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/</p></td></tr></tbody></table><p>&nbsp;</p><p>4.8.2&nbsp;&nbsp;&nbsp; Immunogenicity</p><p>As with all therapeutic proteins, there is potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors, including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies in the studies described below with the incidence of antibodies in other studies or to other romosozumab products may be misleading.</p><p>The immunogenicity of EVENITY was evaluated using an immunoassay for the detection of anti‑romosozumab<em> </em>antibodies. An <em>in vitro</em><em> </em>biological<em> </em>assay was performed to detect neutralizing antibodies for those subjects whose sera tested positive for anti-romosozumab antibodies.</p><p>Among 5914 postmenopausal women treated with EVENITY 210&nbsp;mg monthly, 18.1% of subjects developed antibodies to romosozumab. Of the subjects who developed antibodies to romosozumab, 4.7% had antibodies that were classified as neutralizing. Development of antibodies to romosozumab was associated with lower serum romosozumab concentrations <em>[see Clinical Pharmacology (12.3)]</em>.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>.There is no experience with overdose in clinical trials. There is no known antidote to romosozumab or specific treatment for overdose. In case of overdose, it is recommended that patients are monitored closely and given appropriate treatment.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Mechanism of Action</p><p>&nbsp;</p><p>EVENITY inhibits the action of sclerostin, a regulatory factor in bone metabolism. EVENITY increases bone formation and, to a lesser extent, decreases bone resorption. Animal studies showed that romosozumab stimulates new bone formation on trabecular and cortical bone surfaces by stimulating osteoblastic activity resulting in increases in trabecular and cortical bone mass and improvements in bone structure and strength<em> [see Preclinical Safety data (5.4) and Clinical Studies (5.5)]</em>.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacodynamics</p><p>In postmenopausal women with osteoporosis, EVENITY increased the bone formation marker procollagen type 1 N‑telopeptide (P1NP) with a peak increase from baseline of approximately 145% compared to placebo 2&nbsp;weeks after initiating treatment, followed by a return to concentrations seen with placebo at month&nbsp;9 and a decline from baseline to approximately 15% below the concentration change seen with placebo at month&nbsp;12.</p><p>EVENITY decreased the bone resorption marker type 1 collagen C‑telopeptide (CTX) with a maximal reduction from baseline of approximately 55% compared to placebo 2&nbsp;weeks after initiating treatment. CTX remained below concentrations seen with placebo and was approximately 25% below the concentration change seen with placebo at month&nbsp;12.</p><p>After discontinuation of EVENITY, P1NP levels returned to baseline within 12&nbsp;months; CTX increased above baseline levels within 3&nbsp;months and returned toward baseline levels by month&nbsp;12.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Administration of a single dose of 210&nbsp;mg EVENITY in healthy volunteers resulted in a mean (standard deviation [SD]) maximum romosozumab serum concentration (C<sub>max</sub>) of 22.2 (5.8)&nbsp;mcg/mL and a mean (SD) AUC of 389 (127)&nbsp;mcg*day/mL. Steady‑state concentrations were achieved by month 3 following the monthly administration of 210&nbsp;mg to postmenopausal women. The mean trough serum romosozumab concentrations at months 3, 6, 9, and 12 ranged from 8 to 13&nbsp;mcg/mL.</p><p>&nbsp;</p><p>Romosozumab exhibited nonlinear pharmacokinetics with exposure increasing greater than dose proportionally (e.g., 550‑fold increase in mean AUC<sub>inf</sub> for the 100‑fold increase in subcutaneous doses ranging from 0.1 to 10&nbsp;mg/kg [0.03 to 3.3 times the approved recommended dosage for a 70 kg woman).</p><p>&nbsp;</p><p>&nbsp;</p><p><u>&nbsp;</u></p><p><u>Absorption</u></p><p>&nbsp;</p><p>The median time to maximum romosozumab concentration (T<sub>max</sub>) is 5 days (range: 2 to 7 days).</p><p>&nbsp;</p><p><u>Distribution</u></p><p>The estimated volume of distribution at steady‑state is approximately 3.92&nbsp;L.</p><p><u>Elimination</u></p><p>Romosozumab exhibited nonlinear pharmacokinetics with the clearance of romosozumab decreasing as the dose increased. The estimated mean systemic clearance (CL/F) of romosozumab was 0.38&nbsp;mL/hr/kg, following a single subcutaneous administration of 3&nbsp;mg/kg (the approved recommended dosage for a 70&nbsp;kg woman). The mean effective t<sub>1/2</sub> was 12.8 days after 3 doses of 3&nbsp;mg/kg (the approved recommended dosage for a 70&nbsp;kg woman) every 4 weeks.</p><p><u>Metabolism</u></p><p>The metabolic pathway of romosozumab has not been characterized. As a humanized IgG2 monoclonal antibody, romosozumab is expected to be degraded into small peptides and amino acids via catabolic pathways in a manner similar to endogenous IgG.</p><p><u>Anti-Product Antibody Formation Affecting Pharmacokinetics</u></p><p>Development of anti‑romosozumab antibodies was associated with reduced serum romosozumab concentrations. The presence of anti‑romosozumab antibodies led to decreased mean romosozumab concentrations up to 22%. The presence of neutralizing antibodies led to decreased mean romosozumab concentrations up to 63%<em> [see Undesirable effects (4.8)].</em></p><p><u>Specific Populations</u></p><p>No clinically significant differences in the pharmacokinetics of romosozumab were observed based on age (20-89 years), sex, race, disease state (low bone mass or osteoporosis), prior exposure to alendronate, or renal impairment including end-stage renal disease (ESRD) requiring dialysis. The effect of ESRD not requiring dialysis on the pharmacokinetics of romosozumab is unknown.</p><p><u>Body Weight</u></p><p>The exposure of romosozumab decreases with increasing body weight.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>acetate (3.8&nbsp;mg)</p><p>-&nbsp; calcium (0.61&nbsp;mg)</p><p>-&nbsp; polysorbate 20 (0.07&nbsp;mg)</p><p>-&nbsp; sucrose (70&nbsp;mg) in Water for Injection</p><p>-&nbsp; sodium hydroxide to a pH of 5.2.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <ul><li>Refrigerate EVENITY at 2&deg;C to 8&deg;C in the original carton to protect from light. Do not freeze. Do not shake.</li><li>If removed from the refrigerator, EVENITY can be kept at room temperature up to 25&deg;C in the original carton and must be used within 30&nbsp;days. If not used within 30&nbsp;days, discard EVENITY.&nbsp;</li></ul><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not expose EVENITY to temperatures above 25&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>EVENITY (romosozumab) injection is a clear to opalescent, colorless to light yellow solution for subcutaneous injection supplied in a single‑use prefilled syringe.&nbsp;</p><p>Each single‑use prefilled syringe contains 105&nbsp;mg of EVENITY in a deliverable volume of 1.17&nbsp;mL. To deliver a full dose, inject two 105&nbsp;mg/1.17&nbsp;mL EVENITY prefilled syringes, one after the other for a total dose of 210 mg. Carton of two 105&nbsp;mg/1.17&nbsp;mL (90 mg/mL) single‑use prefilled syringes.</p><p>The prefilled syringe is not made with natural rubber latex.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>.</p><p>The solution should be visually inspected for particles and discoloration prior to administration.</p><p>EVENITY should not be used if the solution is discolored, cloudy, or contains particles.</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                       

EVENITY® (romosozumab)
Manufactured by:
Amgen Inc.
One Amgen Center Drive
Thousand Oaks, California 91320 1799-USA

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                December 2019
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>